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Mold growth in buildings is known to be associated with both allergenic and non-
allergenic effects on population health. The mechanisms by which this process occurs, 
however, are not well understood. The objectives of this study are as follows: 1) Identify 
which transduction pathways are activated in RAW 264.7 cells following mycotoxin and 
glucan exposure, 2) Determine if there is time- and/or dose- dependency, and 3) Identify 
any interactions between mycotoxin and glucan. Molecular techniques will be 
implemented to accomplish these objectives. Results have identified which transduction 
pathways are activated following mycotoxin and glucan exposure. Generally, these 
pathways are up-regulated at lh post exposure (PE) to Neoechinulin A and B. However, 
for glucan exposed AMs, the trend seems to be down-regulation after 30m and lh PE and 
up-regulation after 2h PE. Additionally, this study provides support for both synergistic 
and antagonistic interactions between Neoechinulin A and glucan. 
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Chapter 1 
1.1 General Introduction 
1.2 Introduction to Fungi 
Fungi are common in both outdoor and indoor environments. In outdoor air, mold 
exposure has been linked to respiratory health problems as far back as 400 BC and 
continues to be recognized to date (Dales et al, 1991; Brunekreef et al, 1992; Spengler 
et al, 1994; Garrett et al, 1998; Lander et al, 2001; Pinto et al, 2002). Exposure to 
fungi in outdoor environments has been linked to asthma and allergy. In North America 
alone, about 10% of the population is allergic to Cladosporium, the most commonly 
encountered fungal genus in outdoor air, and dominated by C. cladosporioides and C. 
herbarum. Asthma onset caused by fungal exposures also represents 8% of all hospital 
emergency admissions (NAS, 2000). 
Fungi are also found in indoor air. In healthy, dry buildings, the species 
composition of fungi found indoors is similar to that encountered outdoors. However, in 
damp buildings the composition of fungal species is distinctly different from that 
encountered outdoors. In 15-20% of buildings surveyed in Atlantic Canada some degree 
of water damage, which contributes to fungal growth has been reported (Rand, 1999). 
Additional research has shown that 20-25% of homes in Atlantic Canada have dampness 
problems, which contributes to mold growth. Other areas of Canada and Northern 
temperate areas have also shown comparable results (Murtoniemi, 2003). This is an 
important finding as Canadians have been shown to spend almost 90% of their time 
indoors (Leech et al, 1997). 
In damp buildings, many of the same fungi species that are found outdoors are 
recovered indoors as well, for example, Cladosporium spp. (Rand, 1999). However, the 
most commonly encountered fungi inside damp buildings are anamorphic, soil-dwelling 
Ascomycetes such as Aspergillus spp., Penicillium spp. such as P. aurantiogriseum, P. 
brevicompactum, P. chrysogenum, P. crustosum, P. viridicatum, and a variety of other 
species such as Eurotium herbarorium, Eurotium amstelodami Paecilomyces variotii, 
and Stachybotrys chartarum (Rand, 2005; Slack et ah, 2009), which are mostly 
toxigenic. Indoor inhalation exposure to these types of fungi is recognized as a 
contributing factor to many health problems, including childhood asthma and allergy. 
However, effects associated with indoor fungi differ from those associated with allergy 
and asthma (NAS, 2004). These effects have been related to lower respiratory symptoms 
such as hemoptosis and pulmonary hemosiderosis (Dearborn et al., 1999) in 
environments where individuals are exposed to high spore loads. However, other 
symptoms have been reported; wheeze, cough and headaches (Dales et al., 1991). It is 
thought that the variety of symptoms are linked to exposure to not only fungi that are 
allergenic but also toxigenic. 
The majority of fungal spores are found in settled dust (Ferro et al., 2004). 
Microscopy has revealed that dust contains a mixture of organic particles such as pollen, 
plant material, fungal spores, textile fibers, skin cells, arthropod pieces, insulation fibers, 
and carpet backing and inorganic material such as silica (Rand, 2007). Fungal 
composition in dust can comprise up to 106 to 107 spores/g wt of dust in damp buildings 
(Rand, 2007). Surprisingly, over 60 % of this fungal material in dust is respirable. Ultra 
fine fungal fragments are within the range of 2.5 um and less than l.Oum. In humans, 
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respirable particles are defined as anything equal to or smaller than 5.0 um in diameter. 
There are few quantitative data on the amount of toxins in spores. However, it has been 
reported that the concentrations of mycotoxins in spores and spore fragments are in the 
range of 10"4 - 10"5M (Wicklow and Shotwell, 1983; Sorenson et al., 1987; Miller, 1992). 
1.3 Eurotium amstelodami and neoechinulins 
Eurotium amstelodami is a soil dwelling, xerophilic (dry loving) species that is 
most frequently recovered from tropical and subtropical regions worldwide. In these 
regions, the species is most frequently reported from cultivated soil and a high number of 
isolates have been reported from stored and/or decaying grains, nuts and dried fruit 
samples. Is is not known to be pathogenic, although isolates have been recovered from 
the digestive tract of the honey bee (Apis mellifica). Physiological, developmental and 
cultural characteristics of this species have been the subject of a review by Domsch et al. 
(1993) and for additional information; the reader is referred to this reference. In North 
America, Eurotium amstelodami is commonly found on mold damaged, gypsum 
wallboard, manufactured wood, ceiling tiles, insulation, and textiles that have been damp 
or subject to periodic condensation (Flannigan and Miller, 2001; Miller et al., 2008). 
Eurotium amstelodami is also known to produce mycotoxins. Neoechinulin A & B and 
epiheveadride have been identified as major secondary metabolites of this filamentous 
fungus (Slack et al, 2009). 
1.4 Immune responses to fungi 
Animal studies have clearly shown that exposure to these toxic spores stimulate 
inflammatory lung responses, exhibited as molecular, biochemical, micro-anatomical, 
anatomical and pathophysiological changes (Nikulin et al., 1997; Rao et al., 2000, 2004; 
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Flemming, 2003; Miller et al, 2003; Rand et al, 2005; Rand et al, 2006). Present in the 
fungal spore wall are compounds called mycotoxins. Additional experiments have been 
conducted with purified toxins to determine its effects on the inflammation process. In a 
study conducted by Vanderbilt et al. (2003), freshly isolated alveolar type II cells (ATIIs) 
were found to express certain chemokines, especially the CXC family of 
proinflammatory chemokines following lung injury. Additionally, it was found that ATIIs 
as well as interstitial fibroblasts were highly sensitive to pure mycotoxins isolated from 
Penicillium chrysogenum and Stachybotrys chartarum showing differential up-regulated 
surfactant protein and inflammatory gene expression at toxin concentrations in the low 
nM range (Robbins, 2007). Robbins (2007) also showed distinct gene expression 
differences in ATIIs exposed to both atranones A and C. This was a very interesting 
finding as these two mycotoxins differ only by the presence/absence of a double bond at 
CI2. This type of differential response was also reported by Rand et al. (2006) who 
exposed mice to both atranones A and C resulting in significant differential protein 
expression patterns in the bronchioalveolar lavage fluid (BALF). A similar study that 
exposed primary alveolar macrophages (AMs) to pure toxins isolated from Eurotium 
amstelodami, Eurotium herbariorum Aspergillus versicolor and Penicillium 
brevicompactum also showed differential up- and down- regulation of inflammatory 
genes, which was both toxin and time- dependent (DiPenta, 2008). Another interesting 
finding of the DiPenta (2008) study was differential gene expression patterns in AMs 
following exposure to neoechinulin A and B. These two mycotoxins also differ only by 
the presence/absence of a double bond at C14. Both in vitro and in vivo studies have 
shown that exposure to either pure or spore sequestered mycotoxins leads to depressed 
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alveolar macrophage (AM) activity and an increased inflammatory response (Sorenson et 
ah, 1987; Plascencia and Rosenstein, 1990; Routsalainen et al., 1998). 
With respect to signal transduction pathway activation after immune responses, 
some researchers have predicted that the cell responses to mycotoxins will follow the 
cell-stress activated p38 and/or Jun N-terminal Kinase (JNK) pathways (Raingeaud et al, 
1995; Yang et ah, 2000). When AMs were exposed to Stachybotrys chartarum purified 
toxins (trichothecenes) the mitogen-activated protein kinase (MAPK) pathway was 
activated via the mechanism known as the ribotoxic stress response (Pestka et ah, 2004). 
Wang and Yadav (2007) hypothesized that the Stachybotrys chartarum toxins induce 
multiple signaling pathways in AMs, including MAPK pathways and death receptor 
mediated pathways, and other cross-talk pathways. From these studies, it is clear that 
mycotoxins induce multiple signaling pathways, and that there is evidence suggesting 
there is cross-talk between the pathways. 
Interactions between mycotoxins, fungal and bacterial spores on cell immune 
responses have been studied. Studies show synergistic, antagonistic and additive toxicity 
effects after simultaneous exposures. One study has shown that combinations of 
Stachybotrys chartarum spores with the spores of Streptomyces californicus had a clear 
synergistic effect on the production of an inflammatory mediator (cytokine) in mouse 
macrophages (Huttunen et al., 2004). Another study showed that after exposure to the 
spores of co-cultivated S. californicus and S. chartarum there was a significant influence 
on the regulation of cell cycle arrest compared to either spore alone (Pettinen et al., 
2005). Other studies examining mixtures of mycotoxins also found combination effects 
that were stronger than one mycotoxin alone (Thuvander et al., 1999; Tammer et a l , 
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2007). Tammer et al. (2007) applied an established model for immunotoxic studies using 
stimulated human peripheral blood mononuclear cells (PBMC) and showed that the 
effects on cytokine production of mixtures of mycotoxins was stronger than the effects 
caused by the toxins applied singly. A different study, however, showed no synergistic 
effects, but rather, additive toxicity and antagonistic effects (Thuvander et a l , 1999). 
Human lymphocytes were exposed to a combination of nivalenol and T-2 toxin which 
resulted in additive toxicity. Interestingly, when T-2 toxin was combined with 
deoxynivalenol the result was an inhibition of the proliferative response that was 
significantly lower than the individual toxins which showed an antagonistic action. 
1.5 P-glucans and Dectin-1 
Fungal spore walls, in addition to containing allergens and toxins, are also 
composed of sugars such as beta (P)-glucans. P-Glucans are found in higher plants, some 
bacteria, algae, and fungi (Reid et al, 2004; Dalmo & Bogwalg, 2008; Harada & Ohno, 
2008). P-glucans are a major constituent of the fungal spore cell wall to which they 
provide mechanical strength (Stone and Clarke 1992) via their glucose polymer backbone 
of p (1, 3) linked P-D-glucopyranosyl units with P (1, 6) linked side chains of various 
arrangements (Shematek et al, 1980; Duffus et al, 1982; Williams et al, 1997; Ormstad 
et al, 2000; Harada & Ohno, 2008). P (1, 3) glucans are considered to be potent 
inflammatory mediators due to their linear structure (Young et al, 1998). 
Levels of p (1, 3) D-glucan have been reported in building environments in 
Sweden and can range from 0.1 ng/m3 in office buildings to 106 ng/m3 in houses in 
which mold was evident (Rylander et al, 1992; Rylander et al, 1994). In a separate 
study, an average level of 15.3 ng/m of p (1, 3) glucan was recorded in schools that had 
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reports of mold damage, compared to only 2.9 ng/m3 of p (1, 3) glucan recorded in 
control schools (Rylander et al, 1998). It is important to note that these ranges could 
apply to other regions that have a similar climate as Sweden (Ormstad et al, 2000). In 
urban homes in Ottawa, Miller et al. (2007) reported levels of 1.30 to 1.46 ng/m3 
throughout various parts of the home. The concentrations of p (1, 3) glucan were found to 
vary from area to area. It is highly dependent on environmental factors in the area as well 
as which fungal species are present. 
Most research performed on the pulmonary effects of P (1, 3) glucans has been 
conducted using zymosan and curdlan as models. Zymosan is a glucan derived from yeast 
and is a mixture composed of linear P (1, 3) glucan and a more complex p (1, 6) glucan 
(both present in a 1:1 ratio), mannan, proteins, chitin, and glycolipids (Brown et al, 
2002; Kataoka et al, 2002; Dalmo & Bogwalg, 2008). Curdlan is a pure linear type of P 
(1, 3) glucan produced by bacterial species belonging to the genera Alcaligenes and 
Agrobacterium (Lee, 2005). In a study by Kataoka et al (2002), various P glucans were 
screened for their potential to activate the NF-kB pathway in RAW 264.7 cells. The 
glucans screened by this study included both linear and branched forms of P (1, 3) 
glucan. The results obtained from this study indicate that the linear p (1, 3) glucan 
curdlan exhibits significant cell-stimulating activities, and that the activities of P (1, 3) 
glucans are dependent on their lengths and conformations. 
In vitro studies, using AMs have shown that cells exposed to p glucan produce 
various inflammatory cytokines, in particular TNF (Adachi et al, 1997). Young et al 
(2001) showed that intratracheal instillation of p (1, 3) glucan (zymosan A) induced 
pulmonary inflammation in rats. They observed a variety of pulmonary changes such as 
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increases in respiration, and infiltration of polymorphonucleocytes into the airspace, both 
of which were dose-dependent. An in vivo study by Fogelmark et al. (1997) showed that 
guinea pigs exposed to p (1,3) glucan had increased numbers of eosinophils in their 
airways. Interestingly, the eosinophil numbers found after p (1, 3) glucan exposure were 
decreased by simultaneous exposure to endotoxin (LPS). This finding suggests that 
endotoxin and P (1, 3) glucan activate different inflammatory mechanisms when inhaled. 
Dectin-1 has been identified as the major p (1, 3) glucan receptor and is a small, 
type II transmembrane receptor (Brown and Gordon, 2001) and is classed as a type-C 
lectin, with a carbohydrate recognition domain, a short stalk, and a cytoplasmic tail 
possessing an immunoreceptor tyrosine-base motif (Weis et al, 1998; Ariizumi et al, 
2000; Brown and Gordon, 2001). In humans, dectin-1 is approximately 70% identical to 
the mouse receptor at the amino acid level and both have similar structures and responses 
(Willment et al, 2001). This receptor has been shown to recognize the P-glucans in 
zymosan, Saccharomyces cerevisiae, and heat-killed Candida albicans (Brown and 
Gordon, 2001). Dectin-1 expression on macrophages, neutrophils, monocytes and 
dendritic cells has been demonstrated (Brown et al, 2002; Brown et al, 2003; Willment 
et al, 2003). Dectin-1 has an association with toll-like receptor 2 (TRL2) for initiating 
the immune response in alveolar type II cells exposed to zymosan. Dectin-1 is 
responsible for the reception of p-glucan while the TLR2 binds to an indistinct 
component of the yeast cell wall (Gantner et al, 2003; Willment et al, 2003). 
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1.6 Model System 
Alveolar macrophages (AMs) are vital to lung immune responses against both 
infectious agents such as bacteria and certain fungi and also to non-infectious substances 
such as mycotoxins (Liu et ah, 2002). AMs have been found to play a crucial role in 
phagocytosis of foreign particles, production of mediators of cellular immunity, and 
regulation of T-lymphocyte activity (Gerberick et ah, 1984; Rossi et ah, 1986). Gregory 
et al. (2004) showed that alveolar macrophages respond to mycotoxins. Using 
immunochemistry techniques, localization of satratoxin H was shown in walls of S. 
chartarum spores, its diffusion into inflamed mouse lung tissue surrounding spores, and 
incorporation of the mycotoxin into AM lysosomes. Later studies revealed AM 
recruitment in lungs of animals exposed to S. chartarum spores (Yike et al., 2007). Both 
in vitro and in vivo studies have shown that exposure to either pure or spore sequestered 
mycotoxins leads to depressed AM activity and an increased inflammatory response 
(Sorenson et al, 1987; Plasencia and Rosenstein, 1990). Other studies showed that fungal 
metabolites or toxins may also affect the function of AMs (Sakurai et al., 1997; Ortiz et 
al., 1998). Therefore, changes of any of the molecular features leading to biochemical 
changes of AMs due to toxin exposure could lead to pulmonary and/or systemic damage 
(Jakab et al, 1994). 
1.7 Overall Purpose 
The overall purpose of this study is to provide insight into the molecular 
mechanisms inducing inflammatory responses in AMs. The objectives of this study are as 
follows: 1) Identify which transduction pathways are activated in RAW 264.7 murine 
macrophages (AMs) following mycotoxin and glucan exposure, 2) determine if there is 
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time- and/or dose- dependency, and 3) identify any interactions between mycotoxin and 
glucan. Chapter 2 deals with which transduction pathways are activated in AMs upon 
mycotoxin and glucan exposure, any dose- and/or time-dependent patterns with this 
activation, and cytotoxicity of the compounds tested. Chapter 3 focuses on the outcome 
of any interactions between mycotoxins and glucans. 
It is hypothesized that neoechinulin A, B and P (1, 3) D-glucan will activate 
signal transduction pathways in AMs; that this activation will show differential patterns 
of expression; that it will show time and dose-dependency; and that simultaneous 
exposure to both neoechinulin A and P (1, 3) D-glucan will elicit a synergistic response. 
Chapter 2 - Dose and time dependent responses in AM signal transduction pathways after 
exposure to neoechinulins A & B and P (1, 3) D-glucan. 
2.1 Introduction 
Mold growth in building environments is associated with both allergenic and non-
allergenic effects on population health (NAS, 2004; Health Canada, 2004; WHO, 2004). 
Species found growing indoors comprise a small but dominant proportion of fungi that 
produce mycotoxins (Nielsen et al, 1998; Jarvis, 2002; Nieminen et al, 2002). Most 
species of fungi that are found indoors produce spores that contain relatively high 
concentrations of mycotoxins, but also contain species-specific allergens and proteases 
bound by a cell wall made of P (1, 3) D-glucan (Rand, 2007). 
Eurotium amstelodami is commonly found in indoor environments that suffer 
from water damage (Flannigan and Miller, 2001; Miller et al., 2008). Neoechinulin A & 
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B have been identified as major secondary metabolites of this filamentous fungus (Slack 
et al, 2009). 
The major route of human exposure in indoor environments is by the inhalation of 
toxin-containing spores or free, toxin-contaminated, dust particles (Brasel et al., 2005). 
These inhaled particulates are subjected to phagocytosis and clearance by the host 
alveolar macrophages (AMs) These AMs act as a crucial first line of innate defense in 
the host lung against inhaled particulates (Dorger and Krombach, 2002). For this reason, 
it is important to understand the mechanisms underlying the toxicity of mycotoxins 
towards AMs. 
Eukaryotic cells respond to both intracellular and extracellular stimuli via signal 
transduction pathways. These comprise molecular and biochemical cascades, which in 
turn produce unique responses in the cells. These pathways should not be considered 
mutually exclusive, cross-talk is likely to occur in order to fine tune a cell response to a 
given stimulus. Signal transduction pathways for the immune response have been studied 
and some researchers have predicted that the immune response to mycotoxins will follow 
the cell-stress activated p38 and/or Jun N-terminal Kinase (JNK) pathways (Raingeaud et 
al., 1995). Other researchers have found that AMs exposed to Stachybotrys chartarum 
purified toxins (trichothecenes) activate the mitogen-activated protein kinase (MAPK) 
pathway via the mechanism known as the ribotoxic stress response (Pestka et al., 2004). 
Wang and Yadav (2007) hypothesized that the Stachybotrys chartarum toxins induce 
multiple signaling pathways in AMs, including MAPK pathways, death receptor 
mediated pathways, and related cross-talk. Pathway studies agree that mycotoxins induce 
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multiple signaling pathways, and that there is evidence of cross-talk between the 
pathways. 
The purpose of this study is to determine which transduction pathways are 
stimulated in RAW 264.7 cells following exposure to neoechinulin A & B and P (1, 3) D-
glucan. To determine if there are any dose- and/or time-dependent patterns of expression, 
to determine any cytotoxic properties of these compounds, and also, to determine the no 
observed adverse effect level (NOAEL) for exposure. Based on previous studies 
involving cytokine expression in AMs exposed to neoechinulins and P (1, 3) D-glucan 
(Dipenta, 2008), it is hypothesized that activation of signal transduction pathways will be 
a time- and dose-dependent reaction. 
2.2 Materials and Methods 
2.2.1 Toxins 
Neoechinulin A & B (Fig 1-2) from Eurotium amstelodami were isolated, purified 
and identified, by Dr. David Miller, Department of Chemistry, Carleton University, 
Ottawa. 
Each toxin was dissolved in 1 mL of 100% EtOH and then diluted in 100 mL of 
10% EtOH , endotoxin free saline (PBS) to a concentration of 10"5 M. The solutions were 
diluted into a working solution of 10" M. p (1, 3) D-glucan (curdlan from Alcaligenes 
faecalis (Sigma Aldrich C7821, lot # 89H4032 > 99% purity (from J.D. Miller), which 
was chemically characterized by Foto et al. (2005)) was used as a positive control. P (1, 
3) D-glucan was dissolved in 1 mL of 0.3 M sodium hydroxide and then diluted in 100 
mL PBS to a concentration of 10"5 M. Both toxins and p (1, 3) D-glucan were 
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administered to the cell culture in single doses at concentrations of 10~8, 10"9, 10"10, 10"11 
and 10"12M. 
2.2.2 Cell Culture 
The RAW 264.7 murine macrophage.cell line was obtained from the American 
Type Culture Collection (Rockwille, MD, USA). Cells were maintained at 37°C in a 5% 
CO2 humidified incubator in RPMI 1640 (Invitrogen) medium supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FBS, Invitrogen) and 100 U/ml penicillin and 
100 ug/ml streptomycin (Sigma). Macrophage cell numbers were assessed using a 
hemacytometer. 
2.2.3 Experimental Design 
RAW 264.7 murine macrophages were exposed to neoechinulin A & B for 30m, 
lh and 2h at 10~8, 10"9, 10"10, 10"11 and 10"12M concentrations. Both positive and diluent 
controls were used. P(l,3) D glucan was used as a positive control while the diluents for 
each toxin was used as a diluent control. All experiments were performed in triplicate. 
At the end of the desired exposure time, the reactions were stopped by draining 
the medium and rinsing the flasks with 2ml sterile PBS. Following rinsing, 1.25ml 
RNAlater® was added to each flask, cells were scraped into 2ml eppendorf tubes and 
stored at -80°C. 
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2.2.4 Cell Viability 
AMs were seeded at 30,000 cells/well of a 96-well plate and allowed to adhere 
and grow for 48h. The cells were exposed to neoechinulin A & B, P(l,3) D glucan at 
concentrations ranging from 10"8 to 10'12M and diluent controls for 2h. Following this, 
10 ul MTT reagent was added to the culture medium in the wells of the 96-well plate, and 
incubated for 3h at 37°C. Media was then removed and replaced with 100 ul acidified 
detergent reagent (4 mM HC1, 10% Triton-X in isopropanol). The plate was shaken in the 
dark at room temperature for 15 mins and the absorbance was measured at 570 nm. The 
MTT assay measures the ability of the cells to transform MTT to formazan that can be 
spectrophotometrically detected at a wavelength of 570 nm with a microplate reader. Cell 
viability was calculated as percentage by comparing absorbance values from cells 
exposed to toxins compared with those from corresponding control cells. 
2.2.5 RNA Extraction 
Total RNA isolation was performed using RNeasy® mini kit (Qiagen), according 
to the manufacturer's specifications. Briefly, treatment and control cells were disrupted 
using Buffer RLT (Qiagen) and homogenized using a sterile syringe and needle. Lysate 
was precipitated using 70% EtOH followed by centrifugation (10,000 rpm for 15 sec) in 
an RNeasy column to collect RNA. The column containing RNA was washed in RWI 
buffer (Qiagen), treated with RNase-free DNase to eliminate DNA contamination 
according to manufacturer's instructions (Qiagen), and then washed again with RWI 
followed by two washes with RPE buffer (Qiagen). After washing, RNA was 
resuspended in RNAse/ DNase free water (Sigma Aldrich). The concentration of RNA in 
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samples was determined using a NanoDrop® ND-1000. RNA integrity and purity was 
assessed 260/280 nm and 260/230 ran ratios. Samples with a 260/280 nm ratio of > 2.0 
and a 260/230 nm ratio > 1.90 were used for qPCR analysis. 
2.2.6 Reverse Transcription PCR 
Reverse transcription (RT) Polymerase Chain Reaction (PCR) reactions were 
carried out using a reaction ready first strand cDNA synthesis kit (C-03 SA Biosciences 
®) according to manufacturer's instructions. An annealing mix was prepared first by 
combining 1 ug of RNA with 2 uL of GE Buffer (5x genomic DNA elimination buffer), 
the final volume was adjusted to 10 uL with RNase-free water. This annealing mix was 
preheated at 42°C for 5 minutes then combined with a RT cocktail (4 uL 5x RT buffer 
(BC3), 1 uL primer and external control mix (P2), 2 uL RT enzyme (RE3), and 3 uL of 
RNase-free water). The RT reaction was performed as follows; 42°C for 5 minutes, 
followed by heating at 95°C for 5 minutes to degrade the RNA and inactivate the RE3. 
All cDNA was stored at -20°C. 
2.2.7 Real-time PCR 
Two types of real-time (q) PCR were used in this study. For the transduction 
pathway screening experiments mouse signal transduction pathwayfinder™ PCR arrays 
were used (SA Biosciences # PAMM-014) Following the RT reaction, cDNA samples 
were diluted with 91 uL of RNase-free water. Next, each cDNA sample was combined 
with 200 uL of the PCR SYBR green master mix (SA Biosciences) and 110 uL RNase-
free water. This solution was added in 25 uL aliquots to each well of a 96-well PCR plate 
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for mouse signal transduction pathway finder (SA Biosciences ®). The 96-well plates 
contain primers for specific genes of interest (including housekeeping genes for 
reference). The array contains specific genes representing 18 signal transduction 
pathways, 2 housekeeping genes, a mouse genomic DNA contamination control, 3 
reverse transcription controls, and 3 positive PCR controls (Table 1). The no reverse 
transcription control (NRT) was made through a combination of a 1 in 100 dilution of the 
original RNA in RNase-free water with PCR master mix and RNase-free water. The q 
PCR reactions were carried out using an ABI Prism 7000 Sequence Detection System® 
(Applied Biosystems). A two-step cycling program q PCR reaction was performed 
(Figure 3). The first step was 10 minutes at 95°C to activate the hotstart DNA 
polymerase, next there were 40 cycles for amplification starting at 95 °C for 15 seconds, 
and then the temperature was lowered to 60°C for 60 seconds in order to detect SYBR 
green fluorescence. 
For the dose and time dependent experiments, customized primers and q PCR 
protocols were used. From results of the transduction pathway screening, forward and 
reverse PCR primers for the genes of interest (Table 2) were designed using Primer 3 and 
custom synthesized by Integrated DNA Technologies. The q PCR protocol (Figure 4) 
was carried out on an ABI Prism 7000 Sequence Detection System® (Applied 
Biosystems). A two-step cycling program q PCR reaction was performed. The first step 
was 10 minutes at 95°C to activate the hotstart DNA polymerase, next there were 40 
cycles for amplification starting at 95 °C for 15 seconds, and then the temperature was 
lowered to 55°C for 60 seconds in order to detect SYBR green fluorescence. 
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For both protocols, relative gene expression was determined according to the 
comparative Ct method, with the Actb housekeeping gene and diluent control references 
set as the calibrators. Fold change equals 2M C t , where the Ct is the threshold cycle, ACt is 
the difference between the Q values of the target gene and the internal control gene, 
AAQ represents the difference between the AQ value for the control cells and treated 
cells. 
2.2.8 Statistical Analysis 
A Shapiro-Wilk test for normality was performed to verify if the samples were 
normally distributed. Data (n=3) were then tested for statistical significance using two-
way analysis of variance (ANOVA). Bonferroni post test was also used to examine 
differences between control and treatment gene expression data. Statistical analysis was 
carried out using Graph Pad Prism version 4.0 and results were considered significant at 
a < 0.05 (Gotelli and Ellison, 2004). For graphical representation, data were log 
transformed. For detailed ANOVA tables the reader is referred to appendices I-III, V-VII. 
2.3 Results 
2.3.1 Transduction pathway screening experiment 
In order to determine which transduction pathways are activated, RAW 264.7 
cells were exposed to neoechinulin A & B at 10"8M concentration for 2h. For the rest of 
the experiments, only genes that were significantly regulated are assayed. A heat map 
was generated to assess the degree of gene regulation (Fig 3). 
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l)Neoechinulin A 
After 2h exposure to 10"8M neoechinulin A, AMs showed significant (p < 0.05) down-
regulation of 5 genes representing 7 out of 18 transduction pathways assayed (Table 3). 
These significantly down-regulated genes were Bmp2, Hspbl, Icaml, Vegfa and Cdknlb. 
These genes are indicators for the hedgehog pathway, stress pathway, phospholipase 
c/NFkB pathways, Wnt pathway, and TGF-B pathway, respectively. 
2) Neoechinulin B 
After 2h exposure to 10"8M neoechinlulin B AMs showed significant (p < 0.05) down-
regulation of 2 genes representing 2 out of 18 transduction pathways assayed (Table 3). 
These genes were Bmp2 and Cd5. These genes represent the hedgehog pathway and the 
NFAT pathway, respectively. 
2.3.2 Dose dependant experiments 
For dose-dependent experiments, AMs were exposed to either neoechinulin A, 
neoechinulin B or p (1,3) D glucan at concentrations of 10~8M, 10"9M, 10"10M, 10"nM, 
10"12M. To evaluate time-dependent trends, these experiments were conducted at 30m, 
lh, and 2h time periods. 
1) Bmp2 
Neoechinulin A - Bmp2 was significantly up-regulated at lh PE for 10"8M, 10"9M, 10"10M 
and 10"nM, but not 10"12M. At 2h PE, it was significantly up-regulated atl0"10M, 10"nM 
and 10"12M but not at 10"8M and 10"9M. It was not significantly changed at 30m PE for 
any doses tested (Fig 4 a-c). 
18 
Neoechinulin B - Bmp2 was only found to be significantly up-regulated at lh PE for 10" 
8M. It was not significantly changed at 30m or 2h PE for any doses tested (Fig 4 d-f). 
j5 (1,3) D glucan - At 30m PE, Bmp2 was significantly down-regulated at 10"9M. While 
at lh PE, it was significantly down-regulated for 10"8M and 10"9M exposures. Bmp2 was 
not significantly changed at 2h PE for any doses tested (Fig 4 g-i). 
2) Hspbl 
Neoechinulin A - Hspbl was significantly up-regulated at lh PE for 10"8M, 10"9M, 10" 
10M and 10"nM, but not at 10"12M. At 2h PE, it was found to be significantly up-regulated 
at 10"10M and 10"nM but not at 10"8M, 10"9M and 10"12M. It was not found to be 
significantly changed at 30m PE for any doses tested (Fig 5 a-c). 
Neoechinulin B - At 30m PE, Hspbl was significantly up-regulated for 10"10M, 10"nM 
and 10"12M. At lh PE, it was significantly up-regulated for 10"8M, 10"nM and 10"12M. At 
2h PE, Hspbl was significantly up-regulated for 10"9M and 10"10M and 10"nM only (Fig 
5 d-f). 
P (1,3) D glucan - Hspbl was found to be significantly changed at 30m PE at 10"8M 
only. No changes occurred at other doses tested at 30m, or all doses tested at lh or 2h PE 
compared to controls (Fig 5 g-i). 
3) Icaml 
Neoechinulin A - At both 30m, lh and 2h PE, Icaml was significantly up-regulated at all 
concentrations tested (Fig 6 a-c). 
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Neoechinulin B - At 30m and 2h PE, Icaml was significantly up-regulated at each 
concentration tested. At lh PE, it was significantly up-regulated at 10"8M, 10"9M, 10"nM 
and 10"12M, but not at 10"10M (Fig 6 d-f). 
P (1,3) D glucan - Icaml was significantly down-regulated at 10"8M for lh PE and 
significantly up-regulated at 10"10M for 2h PE. It was not significantly changed at 30m 
PE for any doses tested (Fig 6 g-i). 
4) Vegfa 
Neoechinulin A - Vegfa was significantly up-regulated for every dose tested for 30m, lh 
and 2h PE (Fig 7 a-c). 
Neoechinulin B - At 30m PE, Vegfa was significantly up-regulated for all doses tested. 
At lh PE, it was significantly up-regulated at 10"8M, 10"9M, 10"nM and 10"12M, but not 
for 10"10M. While at 2h PE, it was found to be significantly up-regulated for every dose 
tested (Fig 7 d-f). 
P (1,3) D glucan - At 30m PE, Vegfa was significantly down-regulated at 10"8M. It was 
found to be significantly down-regulated at both 10"8M and 10"nM. Vegfa was 
significantly up-regulated at 2h PE for 10"8M, 10"9M and 10"10M (Fig 7 g-i). 
5) Cdknlb 
Neoechinulin A - At both 30m and lh PE, Cdknlb was significantly up-regulated for 
every dose tested. At 2h PE, it was significantly up-regulated at 10"8M, 10"10M, 10"UM 
and 10"12M, but not at 10"9M (Fig 8 a-c). 
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Neoechinulin B - Cdknlkb was found to be significantly up-regulated at 30m PE for 10" 
8M, 10-10M, 10"nM and 10"12M, but not at 10"9M. At lh and 2h PE, Cdknlb was found to 
be significantly up-regulated for every dose tested (Fig 8 d-f). 
P (1,3) D glucan - Cdknlb was significantly down-regulated at 10"8M and 10"10M after 
30m PE. At lh PE, Cdknlb was significantly down-regulated at 10"8M. At 2h PE, it was 
significantly up-regulated at 10"9M, 10"10M and 10"12M (Fig 8 g-i). 
6) Cd5 
Neoechinulin A — At lh and 2h PE, Cd5 was found to be significantly re-regulated at 10" 
8M, 10"9M, 10"10M and 10"nM, but not for 10"12M. Cd5 was not significantly changed at 
30m PE for any dose tested (Fig 9 a-c). 
Neoechinulin B - At 30m PE, Cd5 was significantly up-regulated at 10"10M and 10"nM. 
At lh PE, it was significantly up-regulated at each concentration tested. At 2h PE, Cd5 
was significantly up-regulated at 10"9M, 10"10M and 10"1 XM (Fig 9 d-f). 
P (1,3) D glucan - Cd5 was significantly up-regulated at 30m PE for 10"10M. At lh PE, 
Cd5 was significantly up-regulated at 10"nM and 10"12M. At 2h PE, Cd5 was 
significantly up-regulated at 10"9M and 10"12M (Fig 9 g-i). 
7)Dectin-l 
Neoechinulin A - At 30m PE, Dectin-1 was found to be significantly up-regulated for 10" 
10M and 10"12M. It was found to be significantly up-regulated at lh PE for 10"10M, 10"nM 
and 10"12M. Dectin-1 was significantly up-regulated at 2h PE for all doses tested (Fig 10 
a-c). 
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Neoechinulin B - Dectin-1 was found to be significantly up-regulated at lh PE for 10" M 
and 10"nM. It was significantly up-regulated at 2h PE for 10"9M, 10"10M, 10"nM and 10" 
M but not 10" M. It was not found to be significantly changed at 30m PE for any dose 
tested (Fig 10 d-f). 
P (1,3) D glucan - At lh PE, Dectin-1 was significantly up-regulated for 10"9M, 10"10M, 
10"nM and 10"12M but not 10"8M. At 2h PE, it was significantly down-regulated at 10"8M 
and up-regulated at 10"9M, 10"10M and 10"nM. Dectin-1 was not significantly changed at 
30m PE for any dose tested (Fig 10 g-i). 
2.3.4 Time dependant experiments 
For time-dependent experiments, AMs were exposed to neoechinulin A & B and P (1,3) 
D glucan at a constant concentration of 10"8M. Experiments were conducted at 30m, lh, 
and 2h exposures. 
1) Neoechinulin A 
AMs exposed to 10"8M neoechinulin A for the three time points showed significant 
(p<0.05) up-regulation for all genes studied. Significantly (p<0.05) up-regulated genes at 
30m post exposure (PE) were Icaml, Vegfa and Cdknlb. At lh PE, significantly (p<0.05) 
up-regulated genes were Bmp2, Hspbl, Icaml, Vegfa, Cdknlb, and Cd5. At 2h PE, 
Icaml, Vegfa, Cdknlb, Cd5 and Dectin-1 were significantly (p<0.05) up-regulated. The 
time-dependent pattern of expression for most genes assayed was up-regulation at each 
time tested with the greatest increase of gene expression at 1 h PE. For Cd5, the pattern is 
different with the same level of increased expression after lh and 2h exposure. For 
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Dectin-1 the time-dependent pattern is also different showing the greatest increase in 
gene expression at 2h PE (Fig 11a). 
2) Neoechinulin B 
AMs exposed to 10"8M neoechinulin B for the three time points showed significant 
(p<0.05) up-regulation for 6 of the 7 genes studied. At 30 m PE Icaml, Vegfa, and 
Cdknlb were significantly (p<0.05) up-regulated. Significantly up-regulated genes at 1 h 
PE were Bmp2, Hspbl, Icaml, Vegfa, Cdknlb, and Cd5. At 2h PE, Icaml, Vegfa, and 
Cdknlb were significantly up-regulated. The time-dependent pattern of expression for 
most genes assayed was up-regulation at each time tested with the greatest increase of 
gene expression at 1 h PE. The only significant difference between the patterns of 
expression for both neoechinulin A and B is Cd5 (Fig lib). 
3)p(l,3)Dglucan 
AMs exposed to 10"8M p (1,3) D glucan for revealed that 6 of the 7 genes studied 
exhibited significant (p<0.05) regulation. At 30m PE, significantly down-regulated genes 
were Hspbl, Vegfa and Cdknlb. At lh PE, Bmp2, Icaml, Vegfa and Cdknlb showed 
significant (p<0.05) down-regulation while significant (p<0.05) up-regulation was 
exhibited by Vegfa at 2h PE. Dectin-1 was significantly (p<0.05) down-regulated at 2h 
PE. The time-dependent pattern of expression for most genes assayed was down-
regulation at 30 m and 1 h PE, followed by up-regulation after 2 h PE (Fig 12). 
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2.3.5 Cytotoxicity Experiment 
AMs were exposed to neoechinulin A, neoechinulin B, p (1,3) D glucan, and diluent 
controls for 2h. Thereafter, an MTT assay was performed to assess toxicity of these 
compounds. Results show that neoechinulin B is cytotoxic to RAW 264.7 cells in culture 
at all doses tested (p < 0.001) compared to diluent control. Neoechinulin A and p (1,3) D 
glucan were not found to be cytotoxic to RAW 264.7 cells in culture at any doses tested 
(Fig 13). 
2.4 Discussion 
The role of alveolar macrophages (AMs) at the molecular level in modulating 
inflammation in toxin treated lungs using an in vitro model of lung disease was examined 
in this study. In this study, transduction pathways involved in the acute modulation of 
acute inflammation were identified. Results indicate that AMs are sensitive to both 
neoechinulin A & B as well as p (1,3) D glucan. These results support previous studies 
by DiPenta (2008) who showed that primary AMs are activated by both neoechinulin A 
and B as well as P (1,3) D glucan and by Kataoka et al. (2002) who showed that P (1,3) 
D glucan activates RAW 264.7 cells. These results are also supported by recent in vivo 
studies by Miller et al. (2009) and Rand et al. (2009) investigated the effect of 
mycotoxins and curdlan on mouse lungs. Mice were intratracheally instilled with a dose 
of 10"5M of either atranone C, brevianamide, cladosporin, mycophenolic acid, 
neoechinulin A & B, sterigmatocystin or TMC-120A or a 10"6M dose of curdlan. 
Immunohistological and PCR based analyses were performed and it was revealed that 
mouse lungs exposed to either mycotoxin or curdlan showed evidence of inflammation 
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such as up-regulation of inflammatory genes as well as expression of dectin-1, MIP-2 and 
TNF on the in bronchiolar epithelium, alveolar macrophages (AMs), and alveolar type II 
cells (ATIIs). 
Although the neoechinulins have been associated with building-related health 
problems, to date no information exists regarding the specific mechanisms for their 
activity in the system. Furthermore, very little information exists regarding the molecular 
basis of their activity. Therefore, the findings of this study will aid greatly in identifying 
the mechanisms by which mycotoxins effect gene expression in AMs. 
This study has shown that compared to controls, 7 of 18 transduction pathway 
genes were significantly modulated after RAW cells were exposed to the three low 
molecular weight compounds tested in this study, and in at least 1 time-point. These were 
bone morphogenic protein 2 (Bmp2), heat shock protein (Hspbl), intercellular adhesion 
molecule 1 (Icaml), vascular endothelial growth factor A (Vegfa), cyclin dependent 
kinase inhibitor (p27) (Cdknlb), lymphocyte antigen (Cd5) and dectin-1. These genes 
correspond to the following pathways, respectively; Hedgehog, stress, phospholipase c, 
NFkB, Wnt, TGF-p\ and NFAT. Of these 7, only 4 are directly involved in the 
inflammatory response. The remaining 3 were still examined in order to broaden our 
knowledge of the mechanisms behind mycotoxin exposure. 
Bone morphogenetic proteins (BMPs) have an essential role in organogenesis and 
tissue repair. This suggests that BMPs may play an important role in airway remodeling. 
They are known to be involved in basal airway homeostasis and that there is an 
accessible reservoir of ligand that can be activated on demand. There are few studies that 
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look at the role of BMP ligands and their signaling pathways in airway inflammatory 
processes. Fukui et al. (2003) showed that Bmp2 expression is activated by the 
proinflammatory cytokines IL-1 and TNF-a. Other BMPs (specifically Bmp7) has been 
shown to modulate the inflammatory response in such ways as inhibiting macrophage 
trafficking and IL-6 expression, and modulating TNF-a-induced proinflammatory gene 
expression (Gould et al, 2002). The hedgehog signaling pathway participates in the 
development of numerous tissues and organs (McMahon et al, 2003). A well known 
effect of reduced hedgehog signaling in human embryos is cyclopia (the formation of 
only one eye). In adults, hedgehog signaling directs the formation of certain stem- and 
precursor-cell populations (Machold et al, 2003). It has been found that increased 
hedgehog signaling in some organs can lead to cancers- of the skin, cerebellum, muscle, 
digestive tract, pancreas or prostate (Pasca di Magliano and Hebrok, 2003). 
Vegfa is in the Vegf family of proteins and is implicated in vascular remodeling 
during embryogenesis, tissue regeneration and carcinogenesis (Shibuya, 2001; Tammela 
et al, 2005; Coultas et al, 2005). Research has shown that hedgehog, Wnt and TGF-f} 
network together during embryogenesis, tissue regeneration and carcinogenesis (Katoh, 
2002; Hooper and Scott, 2005). Hedgehog and Wnt signaling have distinct features, but 
are also sufficiently similar and share enough components to indicate that some aspects 
of the two pathways might have common evolutionary origins. Both pathways are 
activated by seven transmembrane receptors. Both pathways use accessory 
transmembrane protein to regulate the receptor (Nusse, 2003). 
Heat shock proteins (HSPs) function as molecular chaperones. They ensure 
correct folding of proteins into their three-dimensional forms which is crucial for 
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biological activity in the cell or promote degradation of the misfolded proteins and 
regulate cell growth and cell signaling pathways that initiate repair, allow adaptation and 
ensure survival (Lindquist and Craig, 1988; Benjamin and McMillan, 1998; Feder and 
Hofmann, 1999; Agashe and Haiti, 2000). Although the principle function of the HSPs is 
chaperone activity, it has been proposed that they have functions in supporting cellular 
survival under stress conditions by inhibiting apoptosis, stabilization of the cytoskeleton 
and regulation of cell mobility, migration and muscle contraction. Hspbl, specifically, 
has a critical role in mediating protection against stress through maintaining normal cell 
function by stabilizing the cytoskeleton, facilitating repair or removal of damaged 
proteins, and inhibiting components of both stress and death-receptor induced apoptotic 
pathways (Bruey et al, 2000; ; Gerthoffer and Gunst, 2001; Sreedhar and Csermely, 
2004; Didelot et al, 2006). 
Adhesion molecules play integral roles in tumor growth, invasion and metastasis 
and have also been shown to influence the immune responses to malignant cells 
(Simmons, 1995). Human intercellular adhesion molecule (Icaml) belongs to the 
immunoglobulin gene superfamily. Its role has been established as providing signals to 
immune effector cells (Nishio et al, 1996; Uzendoski et al, 1997) and is known to be 
extensively upregulated in inflammatory disorders (Montefort and Holgate, 1991). 
Inflammatory cytokines have been shown to induce the shredding of cell associated 
Icaml (Becker et al, 1991) and detection of a soluble form of Icaml in circulation has 
been proposed to be a useful marker of inflammation (Seth et al, 1991). The NFkB 
signaling pathway coordinates the activation of numerous genes in response to pathogens 
and proinflammatory cytokines (Cohen et al, 1998). NFkB has been demonstrated to 
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respond to a variety of metabolic stress signals, and protects the cell from undergoing cell 
death (Royds et al, 1998). Anahid et al (2003) have shown that NFkB serves as both 
positive and negative regulator of Icaml expression, depending on the stimuli used. 
Phospholipase C signaling has been shown to be involved in the regulated secretion of 
neurotrophins (Canossa et al, 2001). 
Cyclin dependent kinase inhibitor (p27) (Cdknlb) is an endogenous cyclin 
dependent kinase inhibitor (Sherr and Roberts, 1999). The TGF-p signaling pathway 
inhibits cell proliferation by upregulation of Cdkn2b, Cdknla and Cdknlb (Massague et 
al, 2000). Transforming growth factor P (TGF-P) is a potent growth inhibitor for a wide 
variety of cells including immune lymphocytes. Perturbations of the TGF-p signaling 
pathway can result in loss of cell growth regulation (Roberts and Sporn, 1990; Miyazono 
et al, 1994). 
Cd5 (lymphocyte antigen) is a 67 kDa membrane protein that requires activation 
by NFAT signaling (Teutsch et al, 1995). Berland and Wortis (1998) have shown that 
Cd5 expression in B cells requires activation by NFAT. Nuclear factor of activated T cell 
(NFAT) signaling is stimulated by an increase in intracellular Ca2+. This pathway 
controls the transcription of lymphokine genes (eg., IL-2, IL-3, IL-4, IL-5, IFN and TNF-
a), ligand genes (eg., Cd45 and Cd5) and other genes controlling T cell activation, 
apoptosis and cell cycle regulation (Serfling et al., 2000). 
Classical dose-dependent-like responses in gene expression levels were apparent 
in cells exposed to neoechinulin B and p (1,3) D glucan. With a classical response, one 
would expect was the concentration of the compound increases gene expression 
decreases. Trends for this type of response were seen with Vegfa and Hspbl after 2h 
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exposure. Evidence for a classical dose-response response was seen in Cd5 and Dectin-1 
after 2h exposure to neochinulin B. Non-classical dose-dependent-like responses were 
apparent in cells exposed to neoechinulin A. This type of response is the opposite of a 
classical response; when the concentration of the compound decreases gene expression 
increases. Again, trends were seen especially for Hspbl after lh exposure. Evidence for 
this non-classical dose-response was seen in Dectin-1 after both lh and 2h exposure to 
neoechinulin A. However, dose-dependent-like Bmp2 and Hspbl up-regulated expression 
was apparent in cells exposed to high concentration (10"8 M) neoechinulin B at 1 h PE 
and at 10"9 and 10"10 M concentrations at 2 h PE. For p (1,3) D glucan, dose dependency 
was manifest as down-regulated Bmp2 expression in cells exposed to 10-8 and 10-9 M 
curdlan at 1 h PE. It was also apparent in dectin 1 expression in curdlan exposed cells at 1 
and 2 h PE. 
It is evident that signal transduction pathway activation by neoechinulin A & B 
and p (1,3) D glucan exhibit time dependency. A number of other studies have 
demonstrated that responses activated by fungal compounds are time dependent. Alveolar 
Type II cells exposed to S. chartarum and Penicillium chrysogenum purified toxins 
showed different patterns of gene expression showing time-dependence for surfactant 
proteins and inflammatory genes (Robbins, 2007). This same outcome was seen when 
AMs were also exposed to purified mycotoxins (DiPenta, 2008). DiPenta (2008) showed 
rapid, and significant changes in a variety of inflammatory and cell stress-associated 
genes (within 2h PE) in AMs exposed to neoechinulins A and B, sterigmatocystin, 
brevianimide and cladosporin at concentrations of 10" and 10" M. The downstream effect 
of signal transduction pathways are changes in gene expression, cell survival, apoptosis 
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and activation of inflammatory mediators. Therefore, results from DiPenta (2008) would 
indicate that transduction pathway activation would similarly exhibit time dependent 
responses. Time dependent changes in transduction pathway activation associated with 
exposure to fungal compounds is poorly understood. It is interesting that modulation of 
the genes studied here was rapid (within 30m PE). This suggests heightened sensitivity 
and an acute response of RAW 264.7 cells to neoechinulin A and B and the p (1, 3) 
glucan, curdlan. 
This study has shown that neoechinulin B is cytotoxic at the doses tested in RAW 
264.7 cells. It was found that both neoechinulin A and P (1,3) glucan, however, were non 
cytotoxic at any doses tested to RAW 264.7 cells. There is evidence showing different 
levels of cytotoxic effects of many other mycotoxins. Trichothecenes were examined for 
their cytoxotic properties and it was found that type B trichothecenes such as vomitoxin 
and nivalenol were not cytotoxic at the concentrations examined, whereas satratoxin F, 
satratoxin H and T-2 were moderately toxic. In contrast, satratoxin G, roridin A, and 
verrucarin A were highly cytotoxic (Yang et al., 2000). These findings along with the 
findings of Yang et al (2000), support the idea that one species of fungus can produce 
various types of mycotoxins with varying degrees of cytotoxicity. 
One objective of this study was to determine the "no observed adverse effect" 
level (NOAEL). Doses ranging from 10"8M to 10"12M were used in this study and effects 
were still seen in as gene expression changes in AMs after exposure to 10"12M solutions 
of neoechinulin A, B and P (1, 3) glucan. The amount of neoechinulin A or B in the spore 
has not yet been quantified; however this has been determined for some mycotoxins. It 
has been reported that both Aspergillus fumigatus and spores of some Stachybotrys 
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chartarum isolates contain in the order of 10"5M of fumitremorgen A, B and C and 
satratoxin G, respectively (Fisher et al., 2000; Sorenson et al., 1987). It is apparent from 
the results of this study is that the NOAEL varied depending on the compound tested, the 
gene evaluated and the end time point. In general, both neoechinulin A and B showed 
similar trends, especially at lh PE. At this time point, the NOAEL for Vegfa, Icam-1 and 
Cdknlb was less than 10"12M in exposed RAW 264.7 cells. However, for Bmp2 it was 
10"12M for neoechinulin A and 10"9M for neoechinulin B. For Hspbl it was less than 10" 
12M for neoechinulin A and 10"12M for neoechinulin B. For Cd5 the NOAEL was less 
than 10"12M for neoechinulin A and 10"12M for neoechinulin B exposed cells. For P (1,3) 
D glucan exposed cells, the NOAEL ranged from less than 10"12M for Cd5, Dectin-1 and 
Cdknlb, 10"nM for Vegfa, 10"10M for Icaml and 10"9M for Bmp2 to 10'8M Hspbl. These 
results are interesting because they point to the importance of using the responses of 
multiple genes as a means of evaluating the NOAEL. While not explicitly stated in their 
studies, Miller et al. (2009) and Rand et al. (2009) also showed similar results. For 
example, in their study of inflammatory gene expression in mouse lungs stimulated by 
curdlan, only a few of 83 genes were significantly up-regulated at 10"10M concentration 
and at 4h but not at 12h PE while at higher concentrations many more genes were 
expressed at both time points. 
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Chapter 3 - The effects of interactions between neoechinulin A and P (1,3) D glucan on 
AM signal transduction pathway activation. 
3.1 Introduction 
Eurotium amstelodami is commonly found in indoor environments that suffer 
from water damage (Flannigan and Miller, 2001; Miller et ah, 2008). Neoechinulin A & 
B have been identified as major secondary metabolites of this filamentous fungus (Slack 
et al, 2009). 
In indoor environments, mold growth is associated with both allergenic and non-
allergenic effects on population health (NAS, 2004; Health Canada, 2004; WHO, 2004). 
Most species of fungi that grow on moist building materials produce spores that contain 
relatively high concentrations of mycotoxins, species-specific allergens and proteases 
bound by a cell wall made of p (1, 3) D-glucan (Rand, 2007). 
In building environments, humans may be exposed to both mycotoxins and 
glucans as well as other microbial agents (eg, endotoxin). Fungal spores contain species 
specific mixtures of mycotoxins, allergens and proteases bound by a cell wall made of |3 
(1,3) D-glucan (Rand, 2007). Interactions between the different exposures in moisture-
damaged buildings are inevitable, since the spores of a single fungal species alone may 
contain various metabolites, and the moisture-damaged site is a habitat of more than one 
microbial species (Anderson et al., 1997; Nielsen et al., 1999; Hyvarinen et al., 2002) 
Given the widespread occurrence of human exposure to mixtures, these combined effects 
are of major concern. 
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Interactions between mycotoxins, glucan, endotoxin, fungal and bacterial spores 
on cell immune responses have been studied. Studies show synergistic, antagonistic and 
additive toxicity effects after simultaneous exposures. One study has shown that 
combinations of Stachybotrys chartarum spores with the spores of Streptomyces 
californicus had a clear synergistic effect on the production of an inflammatory mediator 
(cytokine) in mouse macrophages (Hutrunen et al., 2004). Another study showed that 
after exposure to the spores of co-cultivated S. californicus and S. chartarum there was a 
significant influence on the regulation of cell cycle arrest compared to either spore alone ^ 
(Pettinen et al., 2005). Other studies examining mixtures of mycotoxins also found 
combination effects that were stronger than one mycotoxin alone (Thuvander et al., 1999; 
Tammer et al., 2007;). Tammer et al. (2007) applied an established model for 
immunotoxic studies using stimulated human peripheral blood mononuclear cells 
(PBMC) and showed that the effects on cytokine production of mixtures of mycotoxins 
was stronger than the effects caused by the toxins applied singly. A different study, 
however, showed no synergistic effects, but rather, additive toxicity and antagonistic 
effects (Thuvander et al., 1999). Human lymphocytes were exposed to a combination of 
nivalenol and T-2 toxin which resulted in additive toxicity. Interestingly, when T-2 toxin 
was combined with deoxynivalenol (DON) the result was an inhibition of the 
proliferative response that was significantly lower than the individual toxins which shows 
an antagonistic action. Folemark et al. (1997) studied the effects of the p (1, 3) D-glucan 
curdlan on the production of eosinophils in the airways of guinea pigs and determined 
there was an increase in these cell numbers after exposure to glucan. This effect was seen 
to decrease after a simultaneous exposure to bacterial endotoxin. 
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The purpose of this study is to examine the response of RAW 264.7 murine 
macrophages (RAW 264.7) after simultaneous exposure to neoechinulin A and |3 (1, 3) 
D-glucan shown as heightened or depressed gene expression. Based on studies that have 
shown that the effects of mixtures of mycotoxins were stronger than one mycotoxin alone 
(Thuvander et al., 1999; Tammer et.al., 2007) it is hypothesized that after exposure to 
two compounds simultaneously, RAW 264.7 cells will have a heightened response shown 
as increased gene expression. 
3.2 Materials and Methods 
3.2.1 Toxins 
Neoechinulin A (Fig 1) from Eurotium amstelodami was isolated, purified and 
identified by Dr. David Miller, Department of Chemistry, Carleton University, Ottawa. 
Neoechinulin A was dissolved in 1 mL 100% EtOH and then diluted in 100 mL of 
10% EtOH, endotoxin free saline (PBS) to a concentration of 10"5 M. P (1, 3) D-glucan 
(from J.D. Miller) was dissolved in 1 mL of 0.3 M sodium hydroxide and diluted in 100 
mL PBS to 10"5 M. These were administered to the cell culture simultaneously at doses of 
10"9 and 10"10M. Neoechinulin A was chosen for this study based on results from chapter 
two's cytoxicity experiment, in which this mycotoxin is shown to be not cytotoxic to 
RAW 264.7 murine macrophages in culture. 
3.2.2 Cell Culture 
The RAW 264.7 murine macrophage cell line was obtained from the American 
Type Cultre Collection (Rockwille, MD, USA). Cells were maintained at 37°C in a 5% 
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CO2 humidified incubator in RPMI (Invitrogen) medium supplemented with 10% (v/v) 
heat inactivated fetal bovine serum (FBS, Invitrogen) and 100 U/ml penicillin and 100 
ug/ml streptomycin (Sigma). Macrophage cell numbers were assessed using a 
hemacytometer. 
3.2.3 Experimental Design 
AMs were exposed to both neoechinulin A and p (1,3) D-glucan simultaneously 
for 30m, lh and 2h at 10"9 and 10"10M concentrations. All experiments were performed in 
triplicate. 
At the end of the desired exposure time, the reactions were stopped by draining 
the medium and rinsing the flasks with 2ml sterile PBS. Following rinsing, 1.25ml 
RNAlater® was added to each flask, cells were scrapped into 2ml eppendorf tubes and 
stored at -80°C. 
3.2.4 RNA Extraction 
Total RNA isolation was performed using RNeasy® mini kit (Qiagen), according 
to the manufacturer's specifications. Briefly, treatment and control cells were disrupted 
using Buffer RLT (Qiagen) and homogenized using syringe and needle, per direction. 
Lysate was precipitated using 70% ETOH followed by centrifugation (at 10,000 rpm for 
15 sec) at 4°C in an RNeasy column to collect RNA. The column containing RNA 
washed in RWI buffer (Qiagen), treated with RNase-free DNase to eliminate DNA 
contamination according to manufacturer's instructions (Sigma Aldrich), and then 
washed with RWI followed by RPE buffer (Qiagen) washes. After washing, RNA was 
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resuspended in RNAse/ DNase free water (Sigma Aldrich. The concentration of RNA in 
samples was determined using a NanoDrop® ND-1000. Samples with 260/280nm ratio 
of > 2.0 and a 260/230nm ratio > 1.90 were used for qPCR analysis. 
3.2.5 Reverse Transcription PCR 
Reverse transcription (RT) Polymerase Chain Reaction (PCR) reactions were 
carried out using a reaction ready first strand cDNA synthesis kit (C-03 SuperArray, 
Bioscience Corp®) according to manufacturer's instructions. An annealing mix was 
prepared first by combining lug of RNA with 2uL of GE Buffer (5x genomic DNA 
elimination buffer), the final volume was adjusted to lOuL with RNase-free water. This 
annealing mix was preheated at 42°C for 5 minutes then combined with a RT cocktail 
(4uL 5x RT buffer (BC3), luL primer and external control mix (P2), 2uL RT enzyme 
(RE3), and 3uL of RNase-free water). The RT reaction was performed; 42°C for 5 
minutes, followed by heating at 95°C for 5 minutes to degrade the RNA and inactivate 
the RE3. All cDNA was stored at -20°C. 
3.2.6 Real-time PCR 
Forward and reverse PCR primers (Table 3) for the genes of interest (Table 2) 
were designed using Primer 3 and custom synthesized by Integrated DNA Technologies. 
The q PCR protocol (Figure 4) was carried out on an ABI Prism 7000 Sequence 
Detection System® (Applied Biosystems). A two-step cycling program q PCR reaction 
was performed. The first step was 10 minutes at 95°C to activate the hotstart DNA 
polymerase, next there were 40 cycles for amplification starting at 95°C for 15 seconds, 
36 
and then the temperature was lowered to 55°C for 60 seconds in order to detect SYBR 
green fluorescence. 
Relative gene expression was determined according to the comparative Q 
method, with the Actb housekeeping gene and diluent control references set as the 
calibrators. Fold change equals 2AACt, where the Ct is the threshold cycle, ACt is the 
difference between the Q values of the target gene and the internal control gene, AAQ 
represents the difference between the AQ value for the control cells and treated cells. 
3.2.7 Statistical Analysis 
A Shapiro-Wilk test for normality was performed to verify if the samples were 
normally distributed. Data (n=3) were then tested for statistical significance using two-
way analysis of variance (ANOVA). Bonferroni post test was also used to examine 
differences between control and treatment gene expression data. Statistical analysis was 
carried out using Graph Pad Prism version 4.0 and results were considered significant at 
a< 0.05 (Gotelli and Ellison, 2004). For graphical representation data was log 
transformed. For detailed ANOVA tables the reader is referred to appendix IV. 
3.3 Results 
3.3.1 Neoechinulin A + p (1,3) D-glucan vs. neoechinulin A or p (1,3) D-glucan 
RAW 264.7 murine macrophages were exposed to both neoechinulin A and P 
(1,3) D-glucan simultaneously at 10"9 and 10"10M concentrations. These experiments were 
conducted at 30m, lh, and 2h time periods. This study was compared to results of gene 
expression changes by either neoechinulin A or p (1,3) D-glucan alone. 
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Bmp2 
The simultaneous exposure to 10"10M neoechinulin A and P (1,3) D-glucan was 
significantly (p < 0.05) reduced than that of neoechinulin A alone after lh post exposure 
(PE) (Fig 15a). 
Hspbl 
The simultaneous exposure to 10"10M neoechinulin A and p (1,3) D-glucan was 
significantly (p < 0.05) reduced than that of neoechinulin A alone after lh post exposure 
(PE) (Fig 15b). 
Icaml 
The simultaneous exposure to 10"9M neoechinulin A and P (1,3) D-glucan was 
significantly (p < 0.05) increased than that of neoechinulin A or P (1,3) D-glucan alone 
after 2h post exposure (PE). It was also significantly greater than that of P (1,3) D-glucan 
alone at 30m, lh and 2h PE at both 10"9M and 10"10M (Fig 14c and Fig 15c). 
Vegfa 
AMs exposed to simultaneous doses of neoechinulin A and p (1,3) D-glucan was found 
to elicit significantly greater responses than that of p (1,3) D-glucan alone at lh and 2h 
PE for 10"9M (Fig 14d) and at 30m, lh and 2h PE for 10-10M (Fig 15d). 
Cdknlb 
There is an increased response in AMs after a simultaneous dose of neoechinulin A and p 
(1,3) D-glucan when compared to just p (1,3) D-glucan alone at lh PE for 10"9M (Fig 
14e) and at 30m and lh PE for 10"10M (Fig 15e). 
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Cd5 
There is no significant change in gene expression for Cd5 when RAW 264.7 murine 
macrophages are exposed to either a simultaneous dose of 10"9M neoechinulin A and P 
(1,3) D-glucan or neoechinulin A or p (1,3) D-glucan alone, however at a simultaneous 
dose of 10"10M, AMs show an increased response at lh PE (Fig 14f and Fig 15f). 
Pectin-1 
There is a significant increase in gene expression for Dectin-1 when AMs are exposed to 
a simultaneous dose of neoechinulin A and p (1,3) D-glucan compared to just P (1,3) D-
glucan alone after 2h PE for both doses tested (Fig 14g and Fig 15g). 
3.4 Discussion 
This study examined the potential interactions between neoechinulin A and P 
(1,3) D-glucan on signal transduction pathway activation in RAW 264.7 murine 
macrophages (AMs). This study was conducted at 30m, lh and 2h PE and at doses of 10"9 
and 10"10M. 
Interactions between mycotoxins and spores have been reported in past studies. 
One study has shown that exposures of combinations of Stachybotrys chartarum spores 
with the spores of Streptomyces californicus had a clear synergistic effect on the 
production of an inflammatory mediator (cytokine) in mouse macrophages (Huttunen et 
al., 2004). Another study revealed that exposure to the spores of co-cultivated S. 
californicus and S. chartarum had a significant influence on the regulation of cell cycle 
arrest (Penttinen et al., 2005). Other studies examining mixtures of mycotoxins also 
found combination effects that were stronger than one mycotoxin alone. These effects 
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were synergistic, antagonistic and additive toxicity effects (Thurvander et al., 1999; 
Tammer et al., 2007). 
This study shows that after lh exposure to a simultaneous dose of 10"10M 
neoechinulin A and p (1,3) D-gluean, there is an antagonistic response of Bmp2 and 
Hspbl (Fig 15). After 2h PE Icaml shows clear synergistic response when RAW 267.4 
cells are exposed to a simultaneous dose of 10"9M neoechinulin A and p (1,3) D-glucan. 
For the other genes tested, however, there doesn't seem to be any statistically significant 
evidence of a synergistic interaction between neoechinulin A and p (1,3) D-glucan (Fig 
14 & 15). There are trends at 2h PE for Bmp2, Hspbl, Vegfa, Cdknlb, Cd5 and dectin-1 
showing a synergistic interaction; however these were not statistically significant. From 
results of chapter 2, we see that generally when AMs were exposed to neoechinulin A 
alone (Fig 11a), gene expression was greater than when exposed to p (1,3) D-glucan 
alone (Fig 12). The results from this study suggest that there may be a masking effect for 
some genes when RAW 267.4 cells are exposed to both neoechinulin A and p (1,3) D-
glucan. However, the nature of this effect remains unclear and should be explored in 
future studies. 
This study shows statistical evidence that simultaneous exposure of RAW 264.7 
cells to neoechinulin A and p (1,3) D-glucan at 10"9M resulted in elevated Icaml, Vegfa 
and Dectin-1 expression after 2h PE (Fig 14) compared to expression in cells exposed to 
these compounds individually This effect was also seen at 10"10M for Icaml, Cdknlb and 
Dectin-1 and at as early as lh PE (Icaml). This result supports the hypothesis that 
exposure to a mixture of compounds elicits a synergistic interaction. At a concentration 
of 10"10M significantly increased Bmp2 and Hspbl expression (Fig 15) was observed in 
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cells exposed to single compounds compared to mixed ones. This antagonistic result is 
interesting because it supports the study by Thurvander et al. (1999) who also showed 
antagonistic responses of mixtures on human lymphocytes. 
These findings highlight the important modulatory effect that mixtures of 
compounds at low concentration have on gene expression. Furthermore, that mycotoxin 
and glucan interactions must be carefully considered when evaluating the possible health 
effects associated with exposure to moisture and mold damaged buildings. 
Chapter 4 
4.1 General Conclusions 
Little information is known about the molecular mechanisms responsible for 
immune responses caused by metabolites of Eurotium amstelodami, neoechinulin A and 
B. Eurotium amstelodami is a xerophilic species commonly recovered from damp 
building materials. The majority of published literature to date focuses on the impact of 
mesophilic and hydrophilic species' metabolites on respiratory health. 
The objectives of this study were three fold; 1) Identify which transduction 
pathways are activated in RAW 264.7 murine macrophages (AMs) following mycotoxin 
and glucan exposure, 2) determine if there is time- and/or dose- dependency, and 3) 
identify any interactions between mycotoxin and glucan. 
This study has shown that after exposure to neoechinulin A, B or p (1,3) glucan 
RAW 264.7 cells express genes for the following pathways; Hedgehog, phospholipase c, 
NFkB, Wnt, TGF-P, and a stress pathway. Although this study focused on the 
mechanisms of the immune response, it was an interesting find that these mycotoxins and 
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curdlan also activate signal transduction pathways that are involved in pathways that are 
not involved in the immune response, such as embryonic development (ie, Hedgehog 
pathway). Up- and/or down-regulation of these genes may have detrimental effects on a 
developing embryo in utero, or young individuals who may be exposed to molds growing 
in damp building environments. The results of this study show that the impact of 
mycotoxins is broader than inflammation alone; the reactions are associated with 
embryogenesis, tissue regeneration, apoptosis and carcinogenesis which support the 
notion that there is a much broader range of effects that require further investigation. 
This study has shown that activation of signal transduction pathways is a time-
dependent phenomenon. Results from this study show that the NOAEL is not only 
dependent on the gene tested but on the end time point as well. 
In addition to determining the effects of neoechinulin A and P (1,3) glucan on 
AMs alone, the final objective of this study was to determine if there were any 
interactions between neoechinulin A and (3 (1,3) glucan seen as heightened or depressed 
gene expression. A clear synergistic effect was seen at both doses tested for Icaml, 
Vegfa, Cdknlb and Dectin-1 at 2h PE. For Bmp2 and Hspbl after lh PE there is evidence 
of an antagonistic interaction. When exposed to both compounds simultaneously there is 
a reduced response compared to the effect of either of the compounds alone. However 
with the other genes tested, the simultaneous exposure is masked by the expression of 
neoechinulin A alone. 
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Table 3 - Significantly regulated genes when AMs are exposed to neoechinulin A & B at 




















Table 4 - qPCR Reaction Parmeters 
Cycles Duration Temperature 
1 10 min 95°C 
15 sec 95°C 
40 1 min 60°C/55°C 
58 
Table 5 - Summary table for gene regulation changes. Values in red indicate down-





















































































































































































































































































































































































Figure 1 - Structure of Neoechinulin A (Slack et al., 2009) 































































































Figure 3 - Summary of results from Transduction Pathway Screening Experiment. Heat 
map showing levels of gene expression in RAW 264.7 cells exposed to 10"8M 
neoechinulin A and B at 2h PE. Green = lowest levels of gene expression; Red = highest 
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Figure 4 - Dose response of Bmp2 after exposure to neoechinulin A & B and P (1, 3) D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row = 
P (1, 3) D glucan. (n = 3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
** indicates significant difference from * 
*** indicates significant difference from both * and ** 
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Figure 5 - Dose response of Hspbl after exposure to neoechinulin A & B and P (1,3) D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row = 
p(1, 3)D glucan. (n = 3 for each treatment) 
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Figure 6 - Dose response of Icaml after exposure to neoechinulin A & B and P (1,3) D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row 
P (1,3) D glucan. (n = 3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
** indicates significant difference from * 
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Figure 7 - Dose response of Vegfa after exposure to neoechinulin A & B and P (1, 3) D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row 
P (1,3) D glucan. (n = 3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
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Figure 8 - Dose response of Cdknlb after exposure to neoechinulin A & B and p(1 ,3)D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row = 
P (1,3) D glucan. (n=3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
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Figure 9 - Dose response of Cd5 after exposure to neoechinulin A & B and P (1, 3) D 
glucan. The 1st column = 0.5h exposure (a,d,g); 2nd column = lh (b,e,h); 3rd = 2h(c,f,i). 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row = 
P (1, 3) D glucan. (n=3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
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Figure 10 - Dose response of Dectin-1 after exposure to neoechinulin A & B and p (1, 3) 
nd i r d . D glucan. The 1st column = 0.5h exposure (a,d,g); 2nQ column = lh (b,e,h); 3ra = 2h(c,f,i) 
The 1st row = neoechinulin A exposure (a,b,c); 2nd row = neoechinulin B (d,e,f); 3rd row 
P (1, 3) D glucan. (n = 3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
** indicates significant-difference from * 
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Figure 11 a-b - Temporal patterns of gene expression in RAW 264.7 murine 
macrophages. A = neoechinulin A 10"8M exposure; B = neoechinulin B 10"8M exposure 
(n=3 for each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
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Figure 12 - Temporal patterns of gene expression in RAW 264.7 murine macrophages 
exposed to 10"8M P (1, 3) D-glucan (n=3 for each treatment) 
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Figure 13 - Assessment of neoechinulin A & B and P (1,3) D-glucan cytotoxicity by 
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Figure 14 - Gene expression changes in AMs after exposure to neoechinulin A and P (1, 
3) D-glucan simultaneously at concentrations of 10"9M for 30m, lh and 2h exposures 
compared to neoechinulin A and p (1, 3) D-glucan alone, a = Bmp2, b = Hspbl, c = 
Icaml, d = Vegfa, e = Cdknlb, f = Cd5, g = Dectin-1. (n=3 for each treatment) 
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Figure 15 - Gene expression changes in AMs after simultaneous exposure to 
neoechinulin A and P (1, 3) D-glucan simultaneously at concentrations of 10"10M for 
30m, lh and 2h exposures compared to neoechinulin A and P (1, 3) D-glucan alone, a = 
Bmp2, b = Hspbl, c = Icaml, d = Vegfa, e = Cdknlb, f = Cd5, g = Dectin-1. (n=3 for 
each treatment) 
* indicates significant regulation (P<0.05) compared to controls 
APPENDIX I - ANOVA TABLES NEO A 
Table Analyzed 
Two-way RM ANOVA 

















Matching by cols 












































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.001 
P > 0.05 
95% CI of diff. 
-8.403 to 1.136 
-16.10 to -6.564 





Table Analyzed 10-8M Hspbl 
Two-way RM ANOVA Matching by cols 































































































P > 0.05 
P<0.01 
P > 0.05 
9 5 % CI of diff. 
-4.740 to 2.606 
-9.306 to -1.960 





Table Analyzed 10-8M Icaml 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






































































95% CI of diff. 
-14.36 to -7.506 
-18.59 to -11.74 





Table Analyzed 10-8M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






































































95% CI of diff. 
-12.78 to -4.356 
-18.71 to-10.29 





Table Analyzed 10-8M Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 































95% CI of diff. 
-10.98 to -4.552 
-15.75 to -9.319 





Table Analyzed 10-8M Cd5 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.01 
P<0.01 
95% CI of diff. 
-4.479 to 3.412 






Table Analyzed 10-8M Dectin-1 
Two-way RM ANOVA Matching by cols 































































































P > 0.05 
P > 0.05 
P < 0.05 
95% CI of diff. 
-6.199 to 1.399 
-3.966 to 3.633 





Table Analyzed 10-9M Bmp2 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P < 0.05 
P > 0.05 
95% CI of diff. 
-3.502 to 6.568 
-9.535 to 0.5352 





Table Analyzed 10-9M Hspbl 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.01 
P > 0.05 
95% CI of diff. 
-5.337 to 2.604 
-9.870 to -1.930 





Table Analyzed 10-9M Icaml 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variat ion 






































































9 5 % CI of diff. 
-14.52 to -6.146 
-15.52 to -7.146 





Table Analyzed 10-9M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






































































95% CI of diff. 
-11.53 to -2.868 
-15.70 to -7.035 





Table Analyzed 10-9M Cdknlb 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 































P > 0.05 
95% CI of diff. 
-11.34 to -1.323 
-12.58 to -2.556 





Table Analyzed 10-9M Cd5 
Two-way RM ANOVA Matching by cols 































































Number of missing values 
Bonferrorti posttests 





























P > 0.05 
P < 0.05 
P < 0.05 
95% CI of diff. 
-3.823 to 2.956 
-6.856 to -0.07710 





Table Analyzed 10-9M Dectin-1 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P > 0.05 
P<0.01 
95% CI of diff. 
-6.174 to 1.708 
-6.708 to 1.174 





Table Analyzed 10-10M Bmp2 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P<0.001 
P < 0.05 
95% CI of diff. 
-5.392 to 4.525 
-12.83 to -2.908 





Table Analyzed 10-10M Hspbl 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






























































P > 0.05 
P<0.01 






95% CI of diff. 
-5.547 to 4.547 
-12.91 to -2.819 





Table Analyzed 10-10M Icaml 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 

































95% CI of diff. 
-16.41 to -9.125 
-14.34 to -7.059 





Table Analyzed 10-10M Vegfa 
Two-way RM ANOVA Matching by cols 































































































9 5 % CI of diff. 
-13.05 to -3 .681 
-16.02 to -6.648 





Table Analyzed 10-10M Cdknlb 
Two-way RM ANOVA Matching by cols 





















P value summary 
ns 
ns 




































Number of missing values 
Bonferroni posttests 
































95% CI of diff. 
-12.20 to -2.605 
-14.56 to-4.971 




* * * 
Table Analyzed 10-10M Cd5 
Two-way RM ANOVA Matching by cols 
















Number of missing val 
Bonferroni posttests 











% of total variation 






































































95% CI of diff. 
-6.580 to 1.714 
-12.01 to -3.720 





Table Analyzed 10-10M Dectin-1 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variat ion 






























































P < 0.05 







9 5 % CI of diff. 
-8.227 to 0.4266 
-8.260 to 0.3932 





Table Analyzed 10-11M Bmp2 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 







































































P > 0.05 
P<0.001 






95% CI of diff. 
-4.467 to 5.533 
-12.93 to -2.933 





Table Analyzed 10-11M Hspbl 
Two-way RM AN OVA Matching by cols 































































































P > 0.05 
P<0.001 
P < 0.05 
95% CI of diff. 
-4.467 to 5.533 
-12.93 to -2.933 





Table Analyzed 10-11M Icaml 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 
































9 5 % CI of diff. 
-16.11 to -7.891 
-17.34 to -9.124 





Table Analyzed 10-11M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing val 
Bonferroni posttests 

















































































95% CI of diff. 
-13.05 to -4.149 
-17.48 to -8.583 





Table Analyzed 10-11M Cdknlb 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 


























































































Table Analyzed 10-11M Cd5 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.001 
P<0.001 
95% CI of diff. 
-4.930 to 2.663 
-11.73 to -4.137 





Table Analyzed 10-11M Dectin-1 
Two-way RM ANOVA Matching by cols 
















% of total variation 














































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P < 0.05 
P<0.001 
95% CI of diff. 
-7.418 to 1.552 
-9.552 to -0.5818 





Table Analyzed 10-12M Bmp2 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Saline Neo A Difference 
15.33 14.43 -0.9 
17.27 15.53 -1.733 
19.27 17.13 -2.133 
9 5 % CI of diff. 
-6.064 to 4.264 
-6.898 to 3.431 










0.5494 P > 0.05 
1.058 P > 0.05 





Table Analyzed 10-12M Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 






























P > 0.05 
P > 0.05 
95% CI of diff. 
-5.806 to 4.606 
-8.739 to 1.673 





Table Analyzed 10-12M Icaml 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 















































































9 5 % CI of diff. 
-14.57 to -5.626 
-16.94 to -7.992 





Table Analyzed 10-12M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variat ion 






































































9 5 % CI of diff. 
-10.75 to -1.583 
-17.02 to -7.850 





Table Analyzed 10-12M Cdknlb 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 
















































































9 5 % CI of diff. 
-11 .11 to -2.753 
-14 .41 to -6.053 





Table Analyzed 10-12M Cd5 
Two-way RM ANOVA Matching by cols 
































































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-6.702 to 1.636 
-5.902 to 2.436 





Table Analyzed 10-12M Dectin-1 
Two-way RM ANOVA Matching by cols 































































Number of missing values 
Bonferroni posttests 





























P < 0.05 
P < 0.05 
P<0.001 
95% CI of diff. 
-8.503 to 0.3700 
-9.503 to -0.6300 





APPENDIX n - ANOVA TABLES NEO B 
Table Analyzed 
Two-way RM ANOVA 

















Matching by cols 












































Number of missing values 
Bonferroni posttests 





Neo B Difference 95% CI of diff. 
15.33 10.83 -4.5 -9.128 to 0.1278 
17.27 6.967 -10.3 -14.93 to -5.672 












P > 0.05 
P<0.001 





Table Analyzed 10-8M Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
16.97 15 -1.967 -7.177 to 3.243 
17.27 9.7 -7.567 -12.78 to-2 .357 













P > 0.05 
P<0.01 





Table Analyzed 10-8M Icaml 
Two-way RM ANOVA Matching by cols 
















% of total variation 

















































































9 5 % CI of diff. 
-13.60 to -6.063 
-17.94 to -10.40 





Table Analyzed 10-8M Vegfa 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 


































9 5 % CI of diff. 
-11.16 to-3 .176 
-18.49 to-10 .51 





Table Analyzed 10-8M Cdknlb 
Two-way RM ANOVA Matching by cols 
















% of total 













































Number of missing values 
Bonferroni posttests 































9 5 % CI of diff. 
-12.77 to -5.229 
-15.44 to -7.896 





Table Analyzed 10-8M Cd5 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
16.97 15.7 -1.267 -7.160 to 4.627 
17.27 8.7 -8.567 -14.46 to-2 .673 













P > 0.05 
P<0.01 





Table Analyzed 10-8M Dectin-1 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P > 0.05 
9 5 % CI of diff. 
-6.133 to 3.400 
-5.566 to 3.966 





Table Analyzed 10-9M Bmp2 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
15.33 14.43 -0.9 -6.067 to 4.267 
17.27 16 -1.267 -6.434 to 3.901 













P > 0.05 
P > 0.05 





Table Analyzed 10-9M Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Saline Neo B Difference 9 5 % CI of diff. 
16.97 15.2 -1.767 -5.403 to 1.870 
17.27 16 -1.267 -4.903 to 2.370 













P > 0.05 






Table Analyzed 10-9M I c a m l . 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
16.97 7.9 -9.067 -12.95 to -5 .183 
17.17 6.2 -10.97 -14.85 to -7 .083 
16.87 6.3 -10.57 -14.45 to -6.683 















Table Analyzed 10-9M Vegfa 
Two-way RM ANOVA Matching by cols 































































































P < 0.05 
P<0.001 
P<0.001 
9 5 % CI of diff. 
-14.15 t o -0 .7857 
-17.51 t o - 4 . 1 5 2 





Table Analyzed 10-9M Cdknlb 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 
















































































9 5 % CI of diff. 
-8 .201 to 1.668 
-15.27 to -5.399 





Table Analyzed 10-9M Cd5 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.001 
P<0.001 
9 5 % CI of diff. 
-5.809 to 1.809 
-10.84 to -3.224 





Table Analyzed 10-9M Dectin-1 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 






























P > 0.05 









Table Analyzed 10-10M Bmp2 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 








































































P > 0.05 
P > 0.05 






9 5 % CI of diff. 
-9.803 to 0.6699 
-6.870 to 3.603 





Table Analyzed 10-10M Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 






























P > 0.05 
P<0.01 
9 5 % CI of diff. 
-13.72 to -6.747 
-5.120 to 1.853 





Table Analyzed 10-10M Icaml 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 
Saline vs. Neo B 
Treatment Saline Neo B Difference 95% CI of diff. 
0.5 16.97 1.8 -15.17 -18.72 to-11.62 
1 17.17 15.63 -1.533 -5.084 to 2.017 




















Table Analyzed 10-10M Vegfa 
Two-way RM ANOVA Matching by cols 



























































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P<0.001 
9 5 % CI of diff. 
-18.99 to -8.475 
-7.858 to 2.658 





Table Analyzed 10-10M Cdknlb 
Two-way RM ANOVA Matching by cols 
















Number of missing val 
Bonferroni posttests 


















































































9 5 % CI of diff. 
-17.46 to -8.144 
-10.82 t o -1 .510 





Table Analyzed 10-10M Cd5 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 
































9 5 % CI of diff. 
-8.032 to -1 .101 
-7.765 to -0.8347 





Table Analyzed 10-10M Dectin-1 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






























































P > 0.05 







9 5 % CI of diff. 
-6.353 to 2.686 
-5.886 to 3.153 





Table Analyzed 10-11M Bmp2 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
15.33 13.13 -2.2 -7.206 to 2.806 
17.27 15.03 -2.233 -7.239 to 2.772 













P > 0.05 
P > 0.05 





Table Analyzed 10-11M Hspbl 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
16.97 8.067 -8.9 -12.56 to-5 .238 
17.27 13.93 -3.333 -6.995 to 0.3282 
19.27 15.73 -3.533 -7.195 to 0.1282 






2.87 P < 0.05 
3.042 P < 0.05 
Summary 
Table Analyzed 10-11M Icaml 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 






























9 5 % CI of diff. 
-18.65 t o -10 .35 
-14.85 to -6.553 





Table Analyzed 10-11M Vegfa 
Two-way RM ANOVA Matching by cols 
















% of total variation 












































Number of missing values 
Bonferroni posttests 





























9 5 % CI of diff. 
-17.52 to -8.879 
-15.52 to -6.879 
-9.821 to -1.179 
Summary 
** 
Table Analyzed 10-11M Cdknlb 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 





Neo B Difference 9 5 % CI of diff. 
16.97 3.6 -13.37 -17.35 to-9 .384 
17.27 7.8 -9.467 -13.45 to -5.484 
19.27 12.63 -6.633 -10.62 to-2 .651 















Table Analyzed 10-11M Cd5 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 















































































9 5 % CI of diff. 
-7.810 to -1.057 
-9.510 to -2.757 





Table Analyzed 10-11M Dectin-1 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









% of total variation 






























































P > 0.05 







9 5 % CI of diff. 
-6.462 to 3.395 
-10.10 t o - 0 . 2 3 8 3 





Table Analyzed 10-12M Bmp2 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





Saline Neo B Difference 9 5 % CI of diff. 
15.33 15.17 -0.1667 -5.474 to 5.141 
17.27 16.57 -0.7 -6.008 to 4.608 
17.27 16.93 -0.3333 -5.641 to 4.974 





0.09899 P > 0.05 
0.4158 P > 0.05 





Table Analyzed 10-12M Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





























P < 0.05 
P < 0.05 
P > 0.05 
9 5 % CI of diff. 
-8.319 to -0.4806 
-7.819 to 0.01942 





Table Analyzed 10-12M Icaml 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





























P < 0.05 
9 5 % CI of diff. 
-15.88 to-6 .586 
-16.71 to -7.420 





Table Analyzed 10-12M Vegfa 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 




























9 5 % CI of diff. 
-12.58 to -2.752 
-15.91 to -6.085 





Table Analyzed 10-12M Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 

















Neo B Difference 9 5 % CI of diff. 
10.13 -6.833 -11.48 to -2 .191 
7.4 -9.867 -14.51 to -5.224 












Table Analyzed 10-12M Cd5 
Two-way RM ANOVA Matching by cols 
















% of total variation 















































Number of missing values 
Bonferroni posttests 
















95% CI of diff. 
-5.985 to 1.985 
-10.15 to-2 .182 










1.582 P > 0.05 
4.879 P<0.01 





Table Analyzed 10-12M Dectin-1 
Two-way RM ANOVA Matching by cols 



























































Number of missing values 
Bonferroni posttests 






























P > 0.05 









APPENDIX in - ANOVA TABLES fi (1,3) GLUCAN 
Table Analyzed 
Two-way RM ANOVA 

















Matchi ing by cols 












































Number of missing values 
Bonferroni posttests 
































P > 0.05 
P<0.001 
P > 0.05 
95% CI of diff. 
-0.5055 to 6.439 
2.194 to 9.139 





Table Analyzed 10-8M Hspbl 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 







































































P < 0.05 
P > 0.05 






9 5 % CI of diff. 
0.03944 to 7.294 
-2.927 to 4.327 





Table Analyzed 10-8M Icaml 
Two-way RM ANOVA Matching by cols 






























































































P > 0.05 
P<0.001 
P > 0.05 
95% CI of diff. 
-1.647 to 8.513 
3.520 to 13.68 





Table Analyzed 10-8M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 








































































P < 0.05 







95% CI of diff. 
0.2934 to 7.373 
0.1268 to 7.207 





Table Analyzed 10-8M Cdknlb 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 








































































P < 0.05 
P<0.001 






95% CI of diff. 
0.1033 to 8.030 
4.170 to 12.10 





Table Analyzed 10-8M Cd5 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 









































































P > 0.05 
P > 0.05 






9 5 % CI of diff. 
-2.164 to 5.431 
-2 .631 to 4.964 





Table Analyzed 10-8M Dectin-1 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P > 0.05 
P<0.001 
95% CI of diff. 
-2.812 to 2.345 
-2.678 to 2.478 





Table Analyzed 10-9M Bmp2 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
9 5 % CI of diff. 
0.6716 to 5.528 
0.4382 to 5.295 





Table Analyzed 10-9M Hspbl 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 







































































: 0 .4667 
P value 
P > 0.05 
P > 0.05 






9 5 % CI of diff. 
-2.900 to 1.834 
-3.767 to 0.9670 





Table Analyzed 10-9M Icaml 
Two-way RM ANOVA Matching by cols 

































































































P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-0.1900 to 2.323 
-2.190 to 0.3234 





Table Analyzed 10-9M Vegfa 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 











































































P > 0.05 







95% CI of diff. 
-2.915 to 2.448 






Table Analyzed 10-9M Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P<0.001 
9 5 % CI of diff. 
-1.474 to 1.874 
-1.907 to 1.440 





Table Analyzed 10-9M Cd5 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P > 0.05 
P < 0.05 
95% CI of diff. 
-3.726 to 0.7930 
-2.426 to 2.093 





Table Analyzed 10-9M Dectin-1 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 
















































































95% CI of diff. 
-3.240 to 0.7069 
-7.907 to -3.960 





Table Analyzed 10-10M Bmp2 
Two-way RM ANOVA Matching by cols 
















Number of missing val 
Bonferroni posttests 









































































P > 0.05 
P > 0.05 






95% CI of diff. 
-1.518 to 3.118 
-1.985 to 2.652 





Table Analyzed 10-lpM Hspbl 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff." 
-2.885 to 2.152 
-3.752 to 1.285 





Table Analyzed 10-10M Icaml 
Two-way RM ANOVA Matching by cols 































































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P > 0.05 
P < 0.05 
95% CI of diff. 
-1.379 to 2.113 






Table Analyzed 10-10M Vegfa 
































































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P < 0.05 
95% CI of diff. 
-2.818 to 2.485 






Table Analyzed 10-10M Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P<0.001 
9 5 % CI of diff. 
-1.427 to 2.827 
-2.360 to 1.894 





Table Analyzed 10-10M Cd5 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 





Saline glucan Difference 
17.37 14.9 -2.467 
16.57 16.4 -0.1667 
16.33 13.3 -3.033 
95% CI of diff. 
-5.102 to 0.1690 
-2.802 to 2.469 
-5.669 to -0.3977 








P < 0.05 
P > 0.05 





Table Analyzed 10-10M Dectin-1 
Two-way RM ANOVA Matching by cols 
















% of total variation 














































































P < 0.05 
P<0.001 
P<0.01 
95% CI of diff. 
-3.787 to-0.1465 
-8.320 to -4.680 





Table Analyzed 10-11M Bmp2 
Two-way RM ANOVA Matching by cols 































































Number of missing values 
Bonferroni posttests 































P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-3.589 to 5.856 
-2.489 to 6.956 





Table Analyzed 10-11M Hspbl 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-4.834 to 4.968 
-7.734 to 2.068 





Table Analyzed 10-11M Icaml 
Two-way RM ANOVA Matching by cols 
















% of total variation 














































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-2.550 to 4.484 
-4.450 to 2.584 





Table Analyzed 10-11M Vegfa 
Two-way RM ANOVA Matching by cols 

































































Number of missing values 
Bonferroni posttests 































P > 0.05 
P < 0.05 
P > 0.05 
9 5 % CI of diff. 
-3.270 to 3.670 
-0.2367 to 6.703 





Table Analyzed 10-11M Cdknlb 
Two-way RM ANOVA Matching by cols 

































































































P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-3.063 to 2.796 
-0.7960 to 5.063 





Table Analyzed 10-11M Cd5 
Two-way RM ANOVA Matching by cols 
































































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P<0.001 
P > 0.05 
95% CI of diff. 
-5.265 to 1.465 
-9.265 to -2.536 





Table Analyzed 10-11M Dectin-1 
Two-way RM ANOVA Matching by cols 































































Number of missing values 
Bonferroni posttests 


























P > 0.05 
P<0.001 




9 5 % CI of diff. 
-3.760 to 0.7596 
-7.760 to -3.240 





Table Analyzed 10-12M Bmp2 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 








































































P > 0.05 
P > 0.05 






95% CI of diff. 
-4.046 to 5.379 
-3.912 to 5.512 





Table Analyzed 10-12M Hspbl 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 






























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-7.341 to 3.674 
-9.774 to 1.241 





Table Analyzed 10-12M Icaml 
Two-way RM ANOVA Matching by cols 
































































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P'> 0.05 
P > 0.05 
95% CI of diff. 
-13.82 to 14.28 
-13.35 to 14.75 





Table Analyzed 10-12M Vegfa 





























































Number of missing values 
Bonferroni posttests 





























P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-15.50 to 13.97 
-10.24 to 19.24 





Table Analyzed 10-12M Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 




























P > 0.05 
P > 0.05 
P < 0.05 
95% CI of diff. 
-4.551 to 3.684 






Table Analyzed 10-12M CdS 
Two-way RM ANOVA Matching by cols 
















Number of missing values 
Bonferroni posttests 
















































































95% CI of diff. 
-6.741 to 0.7406 
-8.574 to -1.093 





Table Analyzed 10-12M Dectin-1 
Two-way RM ANOVA Matching by cols 
















Number of missing val 
Bonferroni posttests 









































































P > 0.05 
P<0.01 






9 5 % CI of diff. 
-6.308 to 0.9747 
-8.775 to -1.492 





APPENDIX IV - ANOVA TABLES NEO A + GLUCAN 
Table Analyzed Bmp2 10-9 
Two-way RM ANOVA Matching by cols 





























































Number of missing values 
Bonferroni posttests 
Neo A + Glucan vs. Neo A 
Treatment 
Treatment 








































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-11.44 to 3.973 
-5.740 to 9.673 





95% CI of diff. 
-12.97 to 2.440 
-13.07 to 2.340 





Table Analyzed Hspbl 10-9 
Two-way RM AN OVA Matching by cols 






























































Number of missing values 0 
Bonferroni posttests 
Neo A + Glucan vs. Neo A 



















P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-9.078 to 4.145 
-3.245 to 9.978 























Glucan Difference 95% CI of diff. 
0.5667 -3.267 -9.878 to 3.345 
1.4 -1.133 -7.745 to 5.478 
0.4667 -4.3 -10 .91 to 2.311 
P value 
1.556 P > 0.05 
0.5397 P > 0.05 





Table Analyzed Icaml 10-9 
Two-way RM AN OVA 
















Matching by cols 












































Number of missing values 
Bonferroni posttests 
Neo A + glucan vs. Neo A 
Treatment 
Treatment 









































P > 0.05 










95% CI of diff. 
-7.876 to 3.809 
-6.809 to 4.876 





95% CI of diff. 
-19.28 to -7.591 
-17.28 to-5.591 





Table Analyzed Vegfa 10-9 
Two-way RM ANOVA 
















Matching by cols 












































Number of missing values 0 
Bonferroni posttests 
Neo A + glucan vs. Neo A 








95% CI of diff. 
-2.692 to 10.03 
-3.426 to 9.292 










1.708 P > 0.05 
1.367 P>0 .05 













Glucan Difference 95% CI of diff. 
0.2667 -3.267 -9.626 to 3.092 
0.9 -7.533 -13.89 to-1.174 
3.433 -8.133 -14.49 t o - 1 . 7 7 4 















Table Analyzed Cdknlb 10-9 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 
Bonferroni posttests 
Neo A + glucan vs. Neo A 
Treatment 
Treatment 





















































P > 0.05 
P > 0.05 






P < 0.05 
P<0.01 
P > 0.05 
95% CI of diff. 
-4.321 to 6.055 
-4.821 to 5.555 





95% CI of diff. 
-10.85 to -0.4788 
-12.15 to -1.779 





Table Analyzed Cd5 10-9 
Two-way RM ANOVA 
















Matching by cols 












































Number of missing values 
Bonferroni posttests 





















































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-9.679 to 1.679 
-4.745 to 6.612 





95% CI of diff. 
-8.645 to 2.712 
-8.012 to 3.345 





Table Analyzed Dectin-1 10-9 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 0 
Bonferroni posttests 
Neo A + glucan vs. Neo A 




Difference 95% CI of diff. 
2.2 0.2 -5.255 to 5.655 
2.767 -2 -7.455 to 3.455 










0.1086 P > 0.05 
1.086 P > 0.05 














Glucan Difference 95% CI of diff. 
1.3 -0.7 -6.155 to 4.755 
5.9 1.133 -4.322 to 6.588 










0.3802 P > 0.05 





Table Analyzed Bmp2 10-10 
Two-way RM ANOVA 
















Matching by cols 












































Number of missing values 
Bonferroni posttests 
Neo A + Glucan vs. Neo A 












95% CI of diff. 
-3.633 to 5.766 
0.7003 to 10.10 
-4.466 to 4.933 





0.6724 P > 0.05 
3.404 P<0.01 





Neo A + Glucan vs. Glucan 




Glucan Difference 95% CI of diff. 
-0.8 -0.1667 -4.866 to 4.533 
-0.3333 -2.8 -7.500 to 1.900 













P > 0.05 
P > 0.05 





Table Analyzed Hspbl 10-10 
Two-way RM AN OVA Matching by cols 






























































Number'of missing values 
Bonferroni posttests 
Neo A + Glucan vs. Neo A 
Treatment 
Treatment 
















































P > 0.05 
P > 0.05 
P > 0.05 
95% CI of diff. 
-4.026 to 3.760 
1.507 to 9.293 





95% CI of diff. 
-5.793 to 1.993 
-5.126 to 2.660 





Table Analyzed Icaml 10-10 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 
Neo A + glucan vs. Neo A 
Treatment 
Treatment 





















































P > 0.05 
P > 0.05 









95% CI of diff. 
-1.752 to 6.686 
-5.386 to 3.052 





95% CI of diff. 
-14.92 to -6.481 
-16.25 to -7.814 
-14.85 to -6.414 
Summary 
* * * 
*** 
*** 
Table Analyzed Vegfa 10-10 
Two-way RM ANOVA 
















Matching by cols 













































Number of missing values 0 
Bonferroni posttests 
Neo A + glucan vs. Neo A 












































P > 0.05 
P > 0.05 









95% CI of diff. 
-4.074 to 5.874 
-3.174 to 6.774 





95% CI of diff. 
-12.27 to -2.326 
-13.91 to -3.959 





Table Analyzed Cdknlb 10-10 
Two-way RM ANOVA Matching by cols 




























































Number of missing values 
Bonferroni posttests 
Neo A + glucan vs. Neo A 












95% CI of diff. 
-4.731 to 6.198 
-4.964 to 5.964 










0.3976 P > 0.05 
0.2711 P > 0.05 












































* * * 
* 
Table Analyzed Cd5 10-10 
Two-way RM ANOVA 
















Matching by cols 












































Number of missing values 
Bonferroni posttests 

















95% CI of diff. 
-3.945 to 5.278 
-1.612 to 7.612 










0.4283 P > 0.05 
1.927 P > 0.05 














Glucan Difference 95% CI of diff. 
2.467 0.7 -3.912 to 5.312 
0.1667 -4.7 -9.312 to -0.08824 










0.4497 P > 0.05 
3.019 P < 0.05 





Table Analyzed Dectin-1 10-10 
Two-way RM ANOVA Matching by cols 






























































Number of missing values 0 
Bonferroni posttests 
Neo A + glucan vs. Neo A 








Neo A + glucan vs. Glucan 
Treatment 
Treatment 





























P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 
P<0.001 
95% CI of diff. 
-2.930 to 7.264 
-5.430 to 4.764 





95% CI of diff. 
-4.864 to 5.330 
-2.897 to 7.297 





APPENDIX V - ANOVA TABLES Neo A Dose Dependence 
Table Analyzed Bmp2 
Two-way RM ANOVA Matching by cols 































































Neo A 10-8 vs. Neo A 10-9 












9 5 % CI of diff. 
-12.83 to 2.496 
-14.50 to 0.8291 










2.329 P > 0.05 
3.081 P < 0.05 





Neo A 10-8 vs. 
Treatment 
Neo A 10-10 












9 5 % CI of diff. 
-10.86 to 4.462 
-11.13 to 4.196 










1.443 P > 0.05 
1.563 P > 0.05 





Neo A 10-8 vs. Neo A 10-11 
Treatment Neo A 10-8 Neo A 10-11 Difference 95% CI of diff. 
0.5 3.633 -0.5333 -4.167 -11.83 to 3.496 
1 11.33 7.933 -3.4 -11.06 to 4.262 










1.878 P > 0.05 
1.533 P > 0.05 





Neo A 10-8 vs. 
Treatment 
Neo A 10-12 








Difference 95% CI of diff. 
-2.733 -10.40 to 4.929 
-9.6 -17.26 to-1.938 










1.232 P > 0.05 
4.328 P<0.001 





Neo A 10-9 vs! Neo A 10-10 
Treatment Neo A 10-9 Neo A 10-10 Difference 95% CI of diff. 
0.5 -1.533 0.4333 1.967 -5.696 to 9.629 
1 4.5 7.867 3.367 -4.296 to 11.03 










0.8866 P > 0.05 
1.518 P > 0.05 





Neo A 10-9 vs. 
Treatment 
Neo A 10-11 












9 5 % CI of diff. 
-6.662 to 8.662 
-4.229 to 11.10 










0.4508 P > 0.05 
1.548 P > 0.05 





Neo A 10-9 vs. Neo A 10-12 












9 5 % CI of diff. 
-5.229 to 10.10 
-10.43 to 4.896 










1.097 P > 0.05 
1.247 P > 0.05 





Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-11 















Difference 9 5 % CI of diff. 
-0.9667 -8.629 to 6.696 
0.06667 -7.596 to 7.729 
-0.8333 -8.496 to 6.829 
P value 
0.4358 P > 0.05 
0.03005 P > 0.05 





Neo A 10-10 vs. Neo A 10-12 
Treatment Neo A 10-10 Neo A 10-12 Difference 95% CI of diff. 
0.5 0.4333 0.9 0.4667 -7.196 to 8.129 
1 7.867 1.733 -6.133 -13.80 to 1.529 
2 5.5 2.133 -3.367 -11.03 to 4.296 
Treatment 







Neo A 10-12 































P > 0.05 
P < 0.05 






P > 0.05 
P < 0.05 















Table Analyzed Hspbl 
Two-way RM ANOVA Matching by cols 





























































Neo A 10-8 vs. 
Treatment 
Neo A 10-9 












9 5 % CI of diff. 
-5.701 to 6.301 
-5.734 to 6.268 










0.1727 P > 0.05 
0.1535 P > 0.05 





Neo A 10-8 vs. Neo A 10-10 
Treatment Neo A 10-8 Neo A10-10 Difference 9 5 % CI of diff. 
0.5 1.067 2.133 1.067 -4.934 to 7.068 
1 5.633 7.867 2.233 -3.768 to 8.234 










0.614 P > 0.05 
1.286 P > 0.05 





Neo A 10-8 vs. Neo A 10-11 













-5.968 to 6.034 
-3.701 to 8.301 










0.01919 P > 0.05 
1.324 P > 0.05 





Neo A 10-8 vs. Neo A 10-12 












9 5 % CI of diff. 
-4.834 to 7.168 
-8.101 to 3.901 
-7.101 to 4.901 
Treatment 






Neo A 10-10 




t P value 
0.6716 P > 0.05 
1.209 P > 0.05 













95% CI of diff. 
-5.234 to 6.768 
-4.034 to 7.968 





Neo A 10-9 vs. Neo A 10-11 





0.4413 P > 0.05 
1.132 P > 0.05 
1.401 P > 0.05 












9 5 % CI of diff. 
-6.268 to 5.734 
-3.968 to 8.034 





Neo A 10-9 vs. Neo A 10-12 





0.1535 P > 0.05 
1.17 P > 0.05 
0.921 P > 0.05 












9 5 % CI of diff. 
-5.134 to 6.868 
-8.368 to 3.634 
-6.934 to 5.068 
Treatment Difference P value Summary 
Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 
























Neo A 10-12 








Neo A 10-12 















































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 




95% CI of diff. 
-7.034 to 4.968 
-5.934 to 6.068 





95% CI of diff. 
-5.901 to 6.101 
-10.33 to 1.668 





95% CI of diff. 
-4.868 to 7.134 
-10.40 to 1.601 





Table Analyzed Icaml 
Two-way RM ANOVA Matching by cols 



























P value summary Significant? 
Df 
Neo A 10-8 vs. 
Treatment 
Neo A 10-9 











































9 5 % CI of diff. 
-6.785 to 5.585 
-10.02 to 2.351 










0.3351 P > 0.05 
2.141 P > 0.05 




Neo A 10-8 vs. 
Treatment 
Neo A 10-10 












9 5 % CI of diff. 
-4.351 to 8.018 
-10.65 to 1.718 






1.024 P > 0.05 
2.495 P > 0.05 





Neo A 10-8 vs. Neo A 10-11 




12 1.067 -5.118 to 7.251 
13.2 -1.967 -8.151 to 4.218 
9.667 0.1667 -6.018 to 6.351 
Treatment 









Neo A 10-12 
Neo A 10-8 




0.5958 P > 0.05 
1.098 P > 0.05 













9 5 % CI of diff. 
-7.018 to 5.351 
-8.885 to 3.485 










0.4655 P > 0.05 
1.508 P > 0.05 




Neo A 10-9 vs. 
Treatment 
Neo A 10-10 












9 5 % CI of diff. 
-3.751 to 8.618 
-6.818 to 5.551 










1.359 P > 0.05 






Neo A 10-9 vs. 
Treatment 
Neo A 10-11 












9 5 % CI of diff. 
-4.518 to 7.851 
-4.318 to 8.051 










0.9309 P > 0.05 
1.043 P > 0.05 




Neo A 10-9 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-6.418 to 5.951 
-5.051 to 7.318 
-6.051 to 6.318 
Treatment Difference P value Summary 
Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 






Neo A 10-11 








Neo A 10-12 








Neo A 10-12 
































Neo A 10 
t 
Neo A 10 
t 























P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 







P > 0.05 
P > 0.05 




95% CI of diff. 
-6.951 to 5.418 
-3.685 to 8.685 





95% CI of diff. 
-8.851 to 3.518 







95% CI of diff. 
-8.085 to 4.285 
-6.918 to 5.451 





Table Analyzed Vegfa 
Two-way RM ANOVA Matching by cols 




























































Neo A 10-8 vs. Neo A 10-9 













95% CI of diff. 
-8.604 to 5.871 
-10.37 to 4.104 










0.6523 P > 0.05 
1.495 P > 0.05 





Neo A 10-8 vs. Neo A 10-10 












95% CI of diff. 
-7.438 to 7.038 
-10.40 to 4.071 






0.09545 P > 0.05 
1.511 P > 0.05 





Neo A 10-8 vs. 
Treatment 
Neo A 10-11 







7.633 -0.9333 -8.171 to 6.304 
13.13 -1.367 -8.604 to 5.871 










0.4455 P > 0.05 
0.6523 P > 0.05 





Neo A 10-8 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-9.671 to 4.804 
-9.304 to 5.171 






1.161 P > 0.05 
0.9864 P > 0.05 

















Difference 9 5 % CI of diff. 
1.167 -6.071 to 8.404 












0.5568 P > 0.05 






Neo A 10-9 vs. 
Treatment 
Neo A 10-11 












' 9 5 % CI of diff. 
-6.804 to 7.671 
-5.471 to 9.004 
-1.071 to 13.40 





0.2068 P > 0.05 
0.8432 P > 0.05 




Neo A 10-9 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-8.304 to 6.171 
-6.171 to 8.304 
0.4289 to 14.90 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 







Neo A 10-11 








Neo A 10-12 








Neo A 10-12 






























Neo A 10 
t 
Neo A 10 
t 



























P > 0.05 







P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 





95% CI of diff. 
-7.971 to 6.504 
-5.438 to 9.038 





95% CI of diff. 
-9.471 to 5.004 
-6.138 to 8.338 





95% CI of diff. 
-8.738 to 5.738 
-7.938 to 6.538 





Table Analyzed Cdknlb 
Two-way RM ANOVA Matching by cols 






























































Neo A 10-8 
Treatment 
Treatment 
Neo A 10-8 
Treatment 
Treatment 





Neo A 10-9 








Neo A 10-10 








Neo A 10-11 



































P > 0.05 







P > 0.05 
P > 0.05 
P > 0.05 
Difference 
95% CI of diff. 
-7.148 to 4.281 
-10.68 to 0.7478 





95% CI of diff. 
-6.081 to 5.348 
-8.481 to 2.948 















-5.748 to 5.681 
-9.548 to 1.881 










0.02015 P > 0.05 
2.317 P > 0.05 





Neo A 10-8 vs. Neo A 10-12 












9 5 % CI of diff. 
-6.548 to 4.881 
-8.014 to 3.414 
-3.548 to 7.881 
Treatment 









Neo A 10-10 





0.5037 P > 0.05 
1.39 P > 0.05 
1.31 P > 0.05 












9 5 % CI of diff. 
-4.648 to 6.781 
-3.514 to 7.914 










0.6448 P > 0.05 






Neo A 10-9 vs. Neo A 10-11 












9 5 % CI of diff. 
-4.314 to 7.114 
-4.581 to 6.848 










0.8463 P > 0.05 






Neo A 10-9 vs. Neo A 10-12 












9 5 % CI of diff. 
-5.114 to 6.314 
-3.048 to 8.381 
1.752 to 13.18 
Treatment Difference P value Summary 
Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 






Neo A 10-11 








Neo A 10-12 








Neo A 10-12 





























Neo A 10 
t 
Neo A 10 
t 


























P > 0.05 







P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 




95% CI of diff. 
-5.381 to 6.048 
-6.781 to 4.648 





95% CI of diff. 
-6.181 to 5.248 
-5.248 to 6.181 





95% CI of diff. 
-6.514 to 4.914 
-4.181 to 7.248 





Table Analyzed Cd5 
Two-way RM ANOVA Matching by cols 






























































Neo A 10-8 vs. Neo A 10-9 
Treatment Neo A 10-8 Neo A 10-9 Difference 95% CI of diff. 
0.5 0.5333 0.4333 -0.1 -5.738 to 5.538 
1 5.133 3.467 -1.667 -7.305 to 3.971 










0.06127 P > 0.05 
1.021 P > 0.05 





Neo A 10-8 vs. 
Treatment 
NeoA 10-10 












9 5 % CI of diff. 
-3.738 to 7.538 
-2.905 to 8.371 






1.164 P > 0.05 
1.675 P > 0.05 





Neo A 10-8 vs. 
Treatment 
Neo A 10-11 







1.133 0.6 -5.038 to 6.238 
7.933 2.8 -2.838 to 8.438 










0.3676 P > 0.05 
1.716 P>0 .05 -





Neo A 10-8 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-3.638 to 7.638 
-9.038 to 2.238 





Neo A 10-9 vs. Neo A 10-10 





1.225 P > 0.05 
2.083 P > 0.05 
1.123 P > 0.05 












9 5 % CI of diff. 
-3.638 to 7.638 
-1.238 to 10.04 










1.225 P > 0.05 
2.696 P < 0.05 
2.206 P > 0.05 
Summary 
Neo A 10-9 vs. 
Treatment 
Neo A 10-11 












9 5 % CI of diff. 
-4.938 to 6.338 
-1.171 to 10.10 





Neo A 10-9 vs. Neo A 10-12 





0.4289 P > 0.05 
2.737 P < 0.05 











9 5 % CI of diff. 
-3.538 to 7.738 
-7.371 to 3.905 
-5.238 to 6.038 
Treatment Difference P value Summary 
Neo A 10-10 vs. 
Treatment 
Treatment 
Neo A 10-10 vs. 
Treatment 
Treatment 






Neo A 10-11 

















Neo A 10-12 








Neo A 10-12 















































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P<0.01 






P > 0.05 
P<0.01 




95% CI of diff. 
-6.938 to 4.338 
-5.571 to 5.705 





95% CI of diff. 
-5.538 to 5.738 
-11.77 to -
0.4953 





95% CI of diff. 
-4.238 to 7.038 
-11.84 to -
0.5620 





Table Analyzed Dectin-1 
Two-way RM ANOVA Matching by cols 





























































Neo A 10-8 
Treatment 
Treatment 
Neo A 10-8 
Treatment 
Treatment 





Neo A 10-9 








Neo A 10-10 








Neo A 10-11 



































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 
P<0.01 
Difference 
95% CI of diff. 
-6.050 to 5.716 
-3.283 to 8.483 





95% CI of diff. 
-4.383 to 7.383 
-2.116 to 9.650 












2.9 0.5333 -5.350 to 6.416 
5.1 4.933 -0.9496 to 10.82 










0.3132 P > 0.05 




Neo A 10-8 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-4.216 to 7.550 
-0.9496 to 10.82 










0.9787 P > 0.05 
2.897 P < 0.05 
2.877 P < 0.05 
Summary 
ns 

















9 5 % CI of diff. 
-4.216 to 7.550 
-4.716 to 7.050 










0.9787 P > 0.05 
0.6851 P > 0.05 





















9 5 % CI of diff. 
-5.183 to 6.583 







Neo A 10-9 vs. Neo A 10-12 












0.411 P > 0.05 














9 5 % CI of diff. 
-4.050 to 7.716 
-3.550 to 8.216 










1.077 P > 0.05 
1.37 P > 0.05 





Neo A 10-10 vs. Neo A 10-11 
Treatment Neo A 10-10 Neo A 10-11 Difference 9 5 % CI of diff. 
0.5 3.867 2.9 -0.9667 -6.850 to 4.916 
1 3.933 5.1 1.167 -4.716 to 7.050 










0.5676 P > 0.05 
0.6851 P > 0.05 





Neo A 10-10 vs. 
Treatment 
Neo A 10-12 












9 5 % CI of diff. 
-5.716 to 6.050 
-4.716 to 7.050 










0.09786 P > 0.05 
0.6851 P > 0.05 





Neo A 10-11 vs. Neo A 10-12 












9 5 % CI of diff. 
-4.750 to 7.016 
-5.883 to 5.883 
-8.283 to 3.483 
Treatment Difference t P value Summary 
0.5 1.133 0.6655 P > 0.05 ns 
1 4.768E-07 0.00000028 P > 0.05 ns 
2 -2.4 1.409 P > 0.05 ns 
APPENDIX VI - ANOVA TABLES Neo B Dose Dependence 
Table Analyzed Bmp2 
Two-way RM ANOVA Matching by cols 


























































Neo B 10-8 vs. 
Treatment 
Treatment 
Neo B 10-8 vs. 
Treatment 
Treatment 
Neo B 10-9 


















































P > 0.05 
P<0.01 






P > 0.05 
P<0.01 
P > 0.05 
95% CI of diff. 
-11.92 to 4.722 
-17.36 t o -
0.7115 





95% CI of diff. 
-8.255 to 8.388 
-16.99 to -
0.3449 





Neo B 10-8 vs. 
Treatment 
Neo B 10-11 












9 5 % CI of diff. 
-10.62 to 6.022 
-16.39 to 0.2551 










0.9547 P > 0.05 
3.348 P<0.01 





Neo B 10-8 vs. Neo B 10-12 
Treatment Neo B 10-8 Neo B 10-12 Difference 9 5 % CI of diff. 
0.5 4.5 0.1667 -4.333 -12.66 to 3.988 
1 10.3 0.7 -9.6 -17.92 t o - 1 . 2 7 8 










1.799 P > 0.05 
3.985 P<0.01 





Neo B 10-9 vs. 
Treatment 
Neo B 10-10 












9 5 % CI of diff. 
-4.655 to 11.99 
-7.955 to 8.688 










1.522 P > 0.05 
0.1522 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-11 












9 5 % CI of diff. 
-7.022 to 9.622 
-7.355 to 9.288 










0.5396 P > 0.05 
0.4013 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-12 











9 5 % CI of diff. 
-9.055 to 7.588 
-8.888 to 7.755 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 








Neo B 10-11 








Neo B 10-12 








































Neo B 1C 
t 






























P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 
P > 0.05 





95% CI of cliff. 
-10.69 to 5.955 
-7.722 to 8.922 





95% CI of diff. 
-12.72 to 3.922 
-9.255 to 7.388 





95% CI of diff. 
-10.36 to 6.288 
-9.855 to 6.788 





Table Analyzed Hspbl 
Two-way RM ANOVA Matching by cols 






























































Neo B 10-8 
Treatment 
Treatment 
Neo B 10-8 
Treatment 
Treatment 





Neo B 10-9 








Neo B 10-10 



























Neo B 10 
t 

















P > 0.05 
P < 0.05 







P < 0.05 
P > 0.05 
Difference 
95% CI of diff. 
-7.079 to 6.679 
-13.18 to 0.5790 





95% CI of diff. 
1.388 to 15.15 
-12.81 to 0.9457 




















-11.11 to 2.646 







2.126 P > 0.05 





Neo B 10-8 vs. 
Treatment 
Neo B 10-12 












9 5 % CI of diff. 
-4.446 to 9.312 
-10.55 to 3.212 










1.222 P > 0.05 
1.841 P > 0.05 





Neo B 10-9 vs. Neo B 10-10 












9 5 % CI of diff. 
1.588 to 15.35 
-6.512 to 7.246 











0.1841 P > 0.05 





Neo B 10-9 vs, 
Treatment 
Neo B 10-11 















9 5 % CI of diff. 
0.2543 to 14.01 
-4.812 to 8.946 











1.038 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-12 








Difference 95% CI of diff. 
2.633 -4.246 to 9.512 
2.633 -4.246 to 9.512 









1.322 P > 0.05 
1.322 P > 0.05 





Neo B 10-10 vs. Neo B 10-11 
Treatment Neo B 10-10 Neo B 10-11 Difference 95%CIofd i f f . 
0.5 10.23 8.9 -1.333 -8.212 to 5.546 
1 1.633 3.333 1.7 -5.179 to 8.579 










0.6695 P > 0.05 
0.8537 P > 0.05 





Neo B 10-10 vs. 
Treatment 
Neo B 10-12 












9 5 % CI of diff. 
-12.71 to 1.046 
-4.612 to 9.146 










2.929 P < 0.05 
1.138 P > 0.05 




Neo B 10-11 vs. Neo B 10-12 
Treatment Neo B 10-11 Neo B 10-12 Difference 95% CI of diff. 
0.5 8.9 4.4 -4.5 -11.38 to 2.379 
1 3.333 3.9 0.5667 -6.312 to 7.446 
2 3.533 2.333 -1.2 -8.079 to 5.679 





2.26 P > 0.05 
0.2846 P > 0.05 





Table Analyzed Icaml 
Two-way RM ANOVA Matching by cols 





























































Neo B 10-8 vs. Neo B 10-9 















9 5 % CI of diff. 
-7.477 to 5.944 
-9.910 to 3.510 






0.3947 P > 0.05 
1.647 P > 0.05 





Neo B 10-8 vs. Neo B 10-10 












9 5 % CI of diff. 
-1.377 to 12.04 
-19.34 to -5.923 






2.745 P < 0.05 
6.503 P<0.001 




Neo B 10-8 vs. Neo B 10-11 







14.5 4.667 -2.044 to 11.38 
10.7 -3.467 -10.18 to 3.244 










2.402 P > 0.05 
1.785 P > 0.05 





Neo B 10-8 vs. Neo B 10-12 












9 5 % CI of diff. 
-5.310 to 8.110 
-8.810 to 4.610 










0.7207 P > 0.05 
1.081 P > 0.05 




Neo B 10-9 vs. Neo B 10-10 












9 5 % CI of diff. 
-0.6104 to 12.81 
-16.14 to -2.723 





Neo B 10-9 vs. Neo B 10-11 





3.14 P < 0.05 
4.856 P<0.001 
0.5834 P > 0.05 










9 5 % CI of diff. 
-1.277 to 12.14 
-6.977 to 6.444 










2.797 P < 0.05 
0.1373 P > 0.05 




Neo B 10-9 vs. 
Treatment 
Neo B 10-12 












9 5 % CI of diff. 
-4.544 to 8.877 
-5.610 to 7.810 
-12.61 to 0.8104 
Treatment Difference P value Summary 
Neo B 10-10 vs. 
Treatment 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 















Neo B 10-12 








Neo B 10-12 





























Neo B 10 
t 
Neo B 10 
t 


























P > 0.05 
P > 0.05 






P > 0.05 
P<0.001 














P > 0.05 
P > 0.05 




95% CI of diff. 
-7.377 to 6.044 
2.456 to 15.88 





95% CI of diff. 
-10.64 to 2.777 






95% CI of diff. 
-9.977 to 3.444 
-5.344 to 8.077 





Table Analyzed Vegfa 
Two-way RM ANOVA Matching by cols 

































Subjects (matching) 10 
Residual 20 
Bonferroni posttests 
Neo B 10-8 vs. Neo B 10-9 





























95% CI of diff. 
-9.879 to 7.679 
-12.45 to 5.113 










0.4328 P > 0.05 
1.443 P > 0.05 





Neo B 10-8 vs. Neo B 10-10 












95% CI of diff. 
-3.613 to 13.95 
-20.68 to -3.121 






2.033 P > 0.05 
4.682 P<0.001 





Neo B 10-8 vs. Neo B 10-11 




13.17 4.6 -4.179 to 13.38 
11.2 -3.3 -12.08 to 5.479 






1.81 P > 0.05 
1.298 P > 0.05 





Neo B 10-8 vs. Neo B 10-12 
Treatment Neo B 10-8 Neo B 10-12 Difference 95% CI of diff. 
0.5 8.567 7.667 -0.9 -9.679 to 7.879 
1 14.5 11 -3.5 -12.28 to 5.279 





Neo B 10-9 vs. Neo B 10-10 





0.3541 P > 0.05 
1.377 P > 0.05 
2.321 P > 0.05 












95% CI of diff. 
-2.513 to 15.05 
-17.01 to 0.5460 










2.466 P > 0.05 
3.24 P<0.01 





Neo B 10-9 vs. Neo B 10-11 
Treatment Neo B 10-9 Neo B 10-11 Difference 95% CI of diff. 
0.5 7.467 13.17 5.7 -3.079 to 14.48 
1 10.83 11.2 0.3667 -8.413 to 9.146 





Neo B 10-9 vs. Neo B 10-12 





2.243 P > 0.05 
0.1443 P > 0.05 
2.138 P > 0.05 












95% CI of diff. 
-8.579 to 8.979 
-8.613 to 8.946 
-13.85 to 3.713 
Treatment Difference P value Summary 
Neo B 10-10 vs. 
Treatment 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 






Neo B 10-11 








Neo B 10-12 








Neo B 10-12 
























































P > 0.05 
P > 0.05 






P > 0.05 
P<0.01 






P > 0.05 
P<0.01 






P > 0.05 
P > 0.05 




95% CI of diff. 
-9.346 to 8.213 
-0.1793 to 17.38 





95% CI of diff. 
-14.85 to 2.713 
-0.3793 to 17.18 





95% CI of diff. 
-14.28 to 3.279 
-8.979 to 8.579 





Table Analyzed Cdknlb 
Two-way RM ANOVA Matching by cols 





























































Neo B 10-8 
Treatment 
Treatment 
Neo B 10-8 
Treatment 
Treatment 





Neo B 10-9 








Neo B 10-10 








Neo B 10-11 






































P > 0.05 
P > 0.05 






P < 0.05 
P<0.01 
P > 0.05 
Difference 
95% CI of diff. 
-11.02 to 2.020 
-8.720 to 4.320 





95% CI of diff. 
-1.487 to 11.55 
-12.89 to 0.1536 












13.37 5.6 -0.9203 to 12.12 
9.467 -3.067 -9.587 to 3.454 





Neo B 10-8 vs. Neo B 10-12 





2.967 P < 0.05 
1.625 P > 0.05 
0.9183 P > 0.05 












95% CI of cliff. 
-7.454 to 5.587 
-9.187 to 3.854 










0.4945 P > 0.05 
1.413 P > 0.05 





Neo B 10-9 vs. Neo B 10-10 
Treatment Neo B 10-9 Neo B 10-10 Difference 95% CI of diff. 
0.5 3.267 12.8 9.533 3.013 to 16.05 
1 10.33 6.167 -4.167 -10.69 to 2.354 











2.207 P > 0.05 





Neo B 10-9 vs. Neo B 10-11 
Treatment Neo B 10-9 Neo B 10-11 Difference 95% CI of diff. 
0.5 3.267 13.37 10.1 3.580 to 16.62 
1 10.33 9.467 -0.8667 -7.387 to 5.654 











0.4592 P > 0.05 




Neo B 10-9 vs. Neo B 10-12 












9 5 % CI of diff. 
-2.954 to 10.09 
-6.987 to 6.054 
-11.35 to 1.687 
Treatment Difference P value Summary 
Neo B 10-10 vs. 
Treatment 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 






Neo B 10-11 








Neo B 10-12 








Neo B 10-12 





























Neo B 10 
t 
Neo B 10 
t 


























P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P < 0.05 
P > 0.05 







P > 0.05 




95% CI of diff. 
-5.954 to 7.087 
-3.220 to 9.820 





95% CI of diff. 
-12.49 to 0.5536 
-2.820 to 10.22 





95% CI of diff. 
-13.05 to -
0.01305 
-6.120 to 6.920 





Table Analyzed Cd5 
Two-way RM ANOVA Matching by cols 






























































Neo B 10-8 vs. 
Treatment 
Neo B 10-9 












95% CI of diff. 
-4.846 to 7.779 
-4.413 to 8.213 









0.8026 P > 0.05 
1.04 P > 0.05 





Neo B 10-8 vs. Neo B 10-10 
Treatment Neo B 10-8 Neo B 10-10 Difference 95% CI of diff. 
0.5 0.5333 4.567 4.033 -2.279 to 10.35 
1 5.133 4.3 -0.8333 -7.146 to 5.479 










2.207 P > 0.05 
0.456 P > 0.05 





Neo B 10-8 vs. Neo B 10-11 







4.433 3.9 -2.413 to 10.21 
6.133 1 -5.313 to 7.313 










2.134 P > 0.05 
0.5472 P > 0.05 





Neo B 10-8 vs. Neo B 10-12 
Treatment Neo B 10-8 Neo B 10-12 Difference 95% CI of diff. 
0.5 0.5333 2 1.467 -4.846 to 7.779 
1 5.133 6.167 1.033 -5.279 to 7.346 










0.8026 P > 0.05 
0.5655 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-10 












95% CI of diff. 
-3.746 to 8.879 
-9.046 to 3.579 










1.405 P > 0.05 
1.496 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-11 












9 5 % CI of diff. 
-3.879 to 8.746 
-7.213 to 5.413 










1.332 P > 0.05 
0.4925 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-12 












9 5 % CI of diff. 
-6.313 to 6.313 
-7.179 to 5.446 
-11.01 to 1.613 
Treatment Difference P value Summary 
Neo B 10-10 vs. 
Treatment 
Treatment 
Neo B 10-10 vs. 
Treatment 
Treatment 















Neo B 10-12 








Neo B 10-12 
























































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 




95% CI of diff. 
-6.446 to 6.179 
-4.479 to 8.146 





95% CI of diff. 
-8.879 to 3.746 
-4.446 to 8.179 





95% CI of diff. 
-8.746 to 3.879 
-6.279 to 6.346 





Table Analyzed Dectin-1 
Two-way RM ANOVA Matching by cols 


































Df Sum-of-squares square 
8 241.9 30.24 
2 286.4 143.2 
4 42.19 10.55 
10 43.2 4.32 






Neo B 10-8 
Treatment 
Treatment 
Neo B 10-8 
Treatment 
Treatment 





Neo B 10-9 








Neo B 10-10 








Neo B 10-11 



































P < 0.05 








P > 0.05 
P<0.01 
Difference 
95% CI of diff. 
-13.25 to 1.247 
-2.447 to 12.05 





95% CI of diff. 
-9.647 to 4.847 
-6.047 to 8.447 









1.533 -2.7 -9.947 to 4.547 
5.167 5 -2.247 to 12.25 






1.287 P > 0.05 
2.383 P > 0.05 





Neo B 10-8 vs. 
Treatment 
Neo B 10-12 








Difference 95% CI of diff. 
-2.467 -9.714 to 4.780 
4.367 -2.880 to 11.61 










1.176 P > 0.05 
2.081 P > 0.05 





Neo B 10-9 vs. 
Treatment 
Neo B 10-10 












9 5 % CI of diff. 
-3.647 to 10.85 
-10.85 to 3.647 






1.716 P > 0.05 
1.716 P > 0.05 





Neo B 10-9 vs, 
Treatment 
Neo B 10-11 












9 5 % CI of diff. 
-3.947 to 10.55 
-7.047 to 7.447 






1.573 P > 0.05 
0.09533 P > 0.05 





Neo B 10-9 vs. Neo B 10-12 












9 5 % CI of diff. 
-3.714 to 10.78 
-7.680 to 6.814 
-13.18 to 1.314 




1.684 P > 0.05 ns 
0.2066 P > 0.05 ns 
2.828 P < 0.05 * 
Neo B 10-10 vs. 
Treatment 
Neo B 10-11 












9 5 % CI of diff. 
-7.547 to 6.947 
-3.447 to 11.05 










0.143 P > 0.05 
1.811 P > 0.05 





Neo B 10-10 vs. Neo B 10-12 
Treatment Neo B 10-10 Neo B 10-12 Difference 95% CI of diff. 
0.5 1.833 1.767 -0.06667 -7.314 to 7.180 
1 1.367 4.533 3.167 -4.080 to 10.41 
2 10.13 5.967 -4.167 -11.41 to 3.080 





0.03178 P > 0.05 
1.509 P > 0.05 





Neo B 10-11 vs. 
Treatment 
Neo B10-12 












9 5 % CI of diff. 
-7.014 to 7.480 
-7.880 to 6.614 










0.1112 P > 0.05 
0.3019 P > 0.05 





APPENDIX V H -
Table Analyzed 
ANOVA TABLES Glucan Dose Dependence 
Bmp2 
Two-way RM ANOVA Matching by cols 





























































glucan 10-8 vs. glucan 10-9 
Treatment glucan 10-8 glucan 10-9 Difference 95% CI of diff. 





2.8 -2.625 to 8.225 
-1.167 -6.591 to 4.258 
Treatment 









































P > o'.05 
P > 0.05 






P > 0.05 
P<0.01 





95% CI of diff. 
-3.258 to 7.591 
-0.1247 to 10.72 





glucan 10-8 vs. glucanlO-11 
Treatment glucan 10-8 glucanlO-11 Difference 95% CI of diff. 
0.5 -2.967 -1.1 1.867 -3.558 to 7.291 
1 -5.633 -2.233 3.4 -2.025 to 8.825 
2 2.2 1 -1.2 -6.625 to 4.225 
Treatment 
glucan 10-8 vs. 
Treatment 
Treatment 



































































P > 0.05 
P > 0.05 






P > 0.05 
P < 0.05 






P > 0.05 
P > 0.05 





9 5 % CI of diff. 
-3.125 to 7.725 
-0.5913 to 10.26 





9 5 % CI of diff. 
-3.158 to 7.691 
-2.925 to 7.925 





glucan 10-9 vs. glucanlO-11 
Treatment glucan 10-9 glucanlO-11 Difference 95% CI of diff. 
0.5 -3.067 -1.1 1.967 -3.458 to 7.391 
1 -2.833 -2.233 0.6 -4.825 to 6.025 










1.252 P > 0.05 
0.3821 P > 0.05 





glucan 10-9 vs. glucan 10-12 
Treatment glucan 10-9 glucan 10-12 Difference 95% CI of diff. 
0.5 -3.067 -0.6667 2.4 -3.025 to 7.825 
1 -2.833 -0.8 2.033 -3.391 to 7.458 










1.528 P > 0.05 
1.295 P > 0.05 





glucan 10-10 vs. glucanlO-l l 
Treatment glucan 10-10 glucanlO-l l Difference 95% CI of diff. 
0.5 -0.8 -1.1 -0.3 -5.725 to 5.125 
1 -0.3333 -2.233 -1.9 -7.325 to 3.525 










0.191 P > 0.05 
1.21 P > 0.05 





glucan 10-10 vs. glucan 10-12 
Treatment glucan 10-10 glucan 10-12 Difference 95% CI of diff. 
0.5 -0.8 -0.6667 0.1333 -5.291 to 5.558 
1 -0.3333 -0.8 -0.4667 -5.891 to 4.958 
2 1.4 4.5 3.1 -2.325 to 8.525 





0.08491 P > 0.05 
0.2972 P > 0.05 
1.974 P > 0.05 
glucanlO-l l vs. glucan 10-12 
Treatment glucanlO-l l glucan 10-12 Difference 
0.5 -1.1 -0.6667 0.4333 
1 -2.233 -0.8 1.433 





9 5 % CI of diff. 
-4.991 to 5.858 
-3.991 to 6.858 










0.2759 P > 0.05 
0.9127 P > 0.05 





Table Analyzed Hspbl 
Two-way RM ANOVA Matching by cols 






























































glucan 10-8 vs. glucan 10-9 
Treatment glucan 10-8 glucan 10-9 Difference 95% CI of diff. 
0.5 -3.633 0.5667 4.2 -1.512 to 9.912 
1 -0.7 1.4 2.1 -3.612 to 7.812 










2.54 P < 0.05 
1.27 P > 0.05 




glucan 10-8 vs. glucan 10-10 
Treatment glucan 10-8 glucan 10-10 Difference 95% CI of diff. 
0.5 -3.633 0.3667 4 -1.712 to 9.712 
1 -0.7 1.233 1.933 -3.778 to 7.645 










2.419 P > 0.05 
1.169 P > 0.05 





glucan 10-8 vs. g lucanl0- l l 







-0.03333 3.6 -2.112 to 9.312 
2.833 3.533 -2.178 to 9.245 










2.177 P > 0.05 
2.137 P>0.05 




















9 5 % CI of diff. 
-0.2117 to 11.21 
-0.7450 to 10.68 











3.004 P < 0.05 
2.58 P < 0.05 
Summary 
** 
glucan 10-9 vs. glucan 10-10 
Treatment glucan 10-9 glucan 10-10 Difference 95% CI of diff. 
0.5 0.5667 0.3667 -0.2 -5.912 to 5.512 
1 1.4 1.233 -0.1667 -5.878 to 5.545 










0.121 P > 0.05 
0.1008 P > 0.05 





glucan 10-9 vs. g lucanl0- l l 
Treatment glucan 10-9 g lucanl0- l l 
0.5 0.5667 -0.03333 
1 1.4 2.833 
2 0.4667 1.133 
Difference 9 5 % CI of diff. 
-0.6 -6.312 to 5.112 
1.433 -4.278 to 7.145 










0.3629 P > 0.05 
0.8669 P > 0.05 





glucan 10-9 vs. glucan 10-12 
Treatment glucan 10-9 glucan 10-12 Difference 95% CI of diff. 
0.5 0.5667 1.867 1.3 -4.412 to 7.012 
1 1.4 4.267 2.867 -2.845 to 8.578 
2 0.4667 4.633 4.167 -1.545 to 9.878 







0.7862 P > 0.05 ns 
1.734 P > 0.05 ns 
2.52 P > 0.05 ns 
glucan 10-10 vs. glucanlO-11 
Treatment glucan 10-10 glucanlO-11 Difference 95% CI of diff. 
0.5 0.3667 -0.03333 -0.4 -6.112 to 5.312 
1 1.233 2.833 1.6 -4.112 to 7.312 










0.2419 P > 0.05 
0.9677 P > 0.05 




















95% CI of diff. 
-4.212 to 7.212 
-2.678 to 8.745 










0.9072 P > 0.05 
1.835 P > 0.05 





glucanlO-11 vs. glucan 10-12 
Treatment glucanlO-11 glucan 10-12 Difference 95% CI of diff. 
0.5 -0.03333 1.867 1.9 -3.812 to 7.612 
1 2.833 4.267 1.433 -4.278 to 7.145 













P > 0.05 
P > 0.05 





Table Analyzed Icaml 
Two-way RM ANOVA Matching by cols 
































































glucan 10-8 vs. 
Treatment 
Treatment 






































1.766 P > 0.05 
6.869 P<0.001 









9 5 % CI of diff. 
-2.327 to 7.194 
4.706 to 14.23 




9 5 % CI of diff. 
-1.661 to 7.861 
3.673 to 13.19 










2.249 P > 0.05 
6.119 P<0.001 





glucan 10-8 vs. g lucanl0- l l 
Treatment glucan 10-8 g lucanl0- l l Difference 95% CI of diff. 
Treatment 
glucan 10-8 vs. 
Treatment 
Treatment 
glucan 10-9 vs. 
Treatment 
Treatment 
glucan 10-9 vs. 
Treatment 
Treatment 

























































































































P > 0.05 
P<0.001 






P > 0.05 
P<0.001 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






-2.261 to 7.261 
4.739 to 14.26 





95% CI of diff. 
-1.494 to 8.027 
3.073 to 12.59 





95% CI of diff. 
-4.094 to 5.427 
-5.794 to 3.727 





95% CI of diff. 
-4.694 to 4.827 
-4.727 to 4.794 





95% CI of diff. 
-3.927 to 5.594 
-6.394 to 3.127 
-3.894 to 5.627 
Summary 
glucan 10-10 vs, 
Treatment 
Treatment 



























































































P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 






P > 0.05 
P > 0.05 




95% CI of diff. 
-5.361 to 4.161 
-3.694 to 5.827 





95% CI of diff. 
-4.594 to 4.927 
-5.361 to 4.161 





95% CI of diff. 
-3.994 to 5.527 
-6.427 to 3.094 





Table Analyzed Vegfa 
Two-way RM ANOVA Matching by cols 































































glucan 10-8 vs. glucan 10-9 















9 5 % CI of diff. 
-1.668 to 9.802 
-1.202 to 10.27 










2.449 P > 0.05 
2.731 P < 0.05 
1.064 P > 0.05 
Summary 
ns 
glucan 10-8 vs. glucan 10-10 
Treatment glucan 10-8 glucan 10-10 Difference 95% CI of diff. 
0.5 -3.8 0.1667 3.967 -1.768 to 9.702 
1 -3.633 0.6 4.233 -1.502 to 9.968 










2.389 P > 0.05 
2.55 P < 0.05 





glucan 10-8 vs. g lucanl0- l l 







-0.2333 3.567 -2.168 to 9.302 
-3.2 0.4333 -5.302 to 6.168 










2.148 P > 0.05 





glucan 10-8 vs. glucan 10-12 
Treatment glucan 10-8 glucan 10-12 Difference 95% CI of diff. 
0.5 -3.8 0.8 4.6 -1.135 to 10.33 
1 -3.633 -4.5 -0.8667 -6.602 to 4.868 





glucan 10-9 vs. glucan 10-10 





2.771 P < 0.05 
0.522 P > 0.05 












9 5 % CI of diff. 
-5.835 to 5.635 
-6.035 to 5.435 





glucan 10-9 vs. g lucanl0- l l 




t P value 
0.06023 P > 0.05 
0.1807 P > 0.05 
0.4016 P > 0.05 












9 5 % CI of diff. 
-6.235 to 5.235 
-9.835 to 1.635 
-9.402 to 2.068 
Treatment Difference t P value Summary 
0.5 -0.5 0.3012 P > 0.05 ns 
1 -4.1 2.47 P > 0.05 ns 
2 -3.667 2.209 P > 0.05 ns 
glucan 10-9 vs. glucan 10-12 
Treatment glucan 10-9 glucan 10-12 Difference 95% CI of diff. 
0.5 0.2667 0.8 0.5333 -5.202 to 6.268 
1 0.9 -4.5 -5.4 -11.13 to 0.3350 
2 3.433 2.467 -0.9667 -6.702 to 4.768 
Treatment Difference P value Summary 
glucan 10-10 vs. 
Treatment 
Treatment 
glucan 10-10 vs, 
Treatment 
Treatment 























































































P > 0.05 
P<0.01 






P > 0.05 
P > 0.05 






P > 0.05 
P < 0.05 






P > 0.05 
P > 0.05 




9 5 % CI of diff. 
-6.135 to 5.335 
-9.535 to 1.935 





9 5 % CI of diff. 
-5.102 to 6.368 
-10.83 to 0.6351 





9 5 % CI of diff. 
-4.702 to 6.768 
-7.035 to 4.435 





Table Analyzed Cdknlb 
Two-way RM ANOVA Matching by cols 





























































glucan 10-8 vs. glucan 10-9 















9 5 % CI of diff. 
-0.9211 to 8.654 
3.579 to 13.15 










2.79 P < 0.05 
6.036 P<0.001 
2.261 P > 0.05 
Summary 
ns 
glucan 10-8 vs. glucan 10-10 
Treatment glucan 10-8 glucan 10-10 Difference 95% CI of diff. 
0.5 -4.067 -0.7 3.367 -1.421 to 8.154 
1 -8.133 0.2333 8.367 3.579 to 13.15 










2.429 P > 0.05 
6.036 P<0.001 





glucan 10-8 vs. glucanlO-11 
Treatment glucan 10-8 glucanlO-11 Difference 95% CI of diff. 
0.5 -4.067 0.1333 4.2 -0.5878 to 8.988 
1 -8.133 -2.167 5.967 1.179 to 10.75 










3.03 P < 0.05 
4.305 P<0.001 




glucan 10-8 vs. glucan 10-12 
Treatment glucan 10-8 glucan 10-12 Difference 95% CI of diff. 
0.5 -4.067 0.4667 4.533 -0.2545 to 9.321 
1 -8.133 -2.333 5.8 1.012 to 10.59 













glucan 10-9 vs. glucan 10-10 
Treatment glucan 10-9 glucan 10-10 Difference 95% CI of diff. 
0.5 -0.2 -0.7 -0.5 -5.288 to 4.288 
1 0.2333 0.2333 0 -4.788 to 4.788 
2 4.767 4.133 -0.6333 -5.421 to 4.154 





0.3607 P > 0.05 
0 P > 0.05 





glucan 10-9 vs. glucanlO-11 
Treatment glucan 10-9 glucanlO-11 Difference 95% CI of diff. 
0.5 -0.2 0.1333 0.3333 -4.454 to 5.121 
1 0.2333 -2.167 -2.4 -7.188 to 2.388 













P > 0.05 
P > 0.05 





glucan 10-9 vs. glucan 10-12 
Treatment glucan 10-9 glucan 10-12 Difference 95% CI of diff. 
0.5 -0.2 0.4667 0.6667 -4.121 to 5.454 
1 0.2333 -2.333 -2.567 -7.354 to 2.221 












P > 0.05 
P > 0.05 





glucan 10-10 vs. glucanlO-11 
Treatment glucan 10-10 glucanlO-11 Difference 95% CI of diff. 
0.5 -0.7 0.1333 0.8333 -3.954 to 5.621 
1 0.2333 -2.167 -2.4 -7.188 to 2.388 













P > 0.05 
P > 0.05 






glucan 10-10 vs. glucan 10-12 
Treatment glucan 10-10 glucan 10-12 Difference 95% CI of diff. 
0.5 -0.7 0.4667 1.167 -3.621 to 5.954 
1 0.2333 -2.333 -2.567 -7.354 to 2.221 













P > 0.05 
P > 0.05 






glucanlO-11 vs. glucan 10-12 
Treatment glucanlO-11 glucan 10-12 Difference 95% CI of diff. 
0.5 0.1333 0.4667 0.3333 -4.454 to 5.121 
1 -2.167 -2.333 -0.1667 -4.954 to 4.621 













P > 0.05 
P > 0.05 





Table Analyzed Cd5 
Two-way RM ANOVA Matching by cols 





























































glucan 10-8 vs. glucan 10-9 
Treatment glucan 10-8 glucan 10-9 
0.5 -1.633 1.467 
1 -1.167 0.2 
2 -1.333 2.1 
Difference 95% CI of diff. 
3.1 -1.434 to 7.634 
1.367 -3.167 to 5.901 










2.362 P > 0.05 
1.041 P > 0.05 




glucan 10-8 vs. glucan 10-10 
Treatment glucan 10-8 glucan 10-10 Difference 95% CI of diff. 
0.5 -1.633 2.467 4.1 -0.4339 to 8.634 
1 -1.167 0.1667 1.333 -3.201 to 5.867 










3.124 P < 0.05 





glucan 10-8 vs. g lucanl0- l l 
Treatment glucan 10-8 g lucanl0- l l Difference 95% CI of diff. 
Treatment 




















































P < 0.05 
P<0.001 









-1.001 to 8.067 
2.533 to 11.60 





95% CI of diff. 
0.09945 to 
9.167 
1.466 to 10.53 




glucan 10-9 vs. glucan 10-10 
Treatment glucan 10-9 glucan 10-10 Difference 95% CI of diff. 
0.5 1.467 2.467 1 -3.534 to 5.534 
1 0.2 0.1667 -0.03333 -4.567 to 4.501. 












P > 0.05 
P > 0.05 





glucan 10-9 vs. g lucanl0- l l 
Treatment glucan 10-9 glucanlO-11 Difference 95% CI of diff. 
0.5 1.467 1.9 0.4333 -4.101 to 4.967 
1 0.2 5.9 5.7 1.166 to 10.23 





glucan 10-9 vs. glucan 10-12 




















P > 0.05 
P<0.001 









95% CI of diff. 
-3.001 to 6.067 
0.09945 to 
9.167 












P > 0.05 
P<0.01 





glucan 10-10 vs. glucanlO-11 
Treatment glucan 10-10 glucanlO-11 Difference 95% CI of diff. 
0.5 2.467 1.9 -0.5667 -5.101 to 3.967 
1 0.1667 5.9 5.733 1.199 to 10.27 
2 3.067 1.667 -1.4 -5.934 to 3.134 
Treatment 





































































P > 0.05 
P<0.001 






P > 0.05 
P<0.01 






P > 0.05 
P > 0.05 





95% CI of diff. 
-4.001 to 5.067 
0.1328 to 9.201 





95% CI of diff. 
-3.434 to 5.634 
-5.601 to 3.467 





Table Analyzed Dectin-1 
Two-way RM ANOVA Matching by cols 
























































glucan 10-8 vs. glucan 10-9 
Treatment glucan 10-8 glucan 10-9 Difference 
0.5 0.2667 1.3 1.033 
1 0.1333 5.9 5.767 
-8.767 2.333 
9 5 % CI of diff. 
-2.779 to 4.846 
1.954 to 9.579 

















glucan 10-8 vs. glucan 10-10 
Treatment glucan 10-8 glucan 10-1.0 Difference 95% CI of diff. 
0.5 0.2667 1.933 1.667 -2.146 to 5.479 
1 0.1333 6.467 6.333 2.521 to 10.15 

















glucan 10-8 vs. g lucanl0- l l 
Treatment glucan 10-8 g lucanl0- l l Difference 95% CI of diff. 
Treatment 
glucan 10-8 vs. 
Treatment 
Treatment 
glucan 10-9 vs. 
Treatment 
Treatment 
glucan 10-9 vs. 
Treatment 
Treatment 






































































































































P > 0.05 
P > 0.05 






P > 0.05 






-2.546 to 5.079 
1.554 to 9.179 





9 5 % CI of diff. 
-1.446 to 6.179 
1.221 to 8.846 





9 5 % CI of diff. 
-3.179 to 4.446 
-3.246 to 4.379 





9 5 % CI of diff. 
-3.579 to 4.046 
-4.212 to 3.412 




9 5 % CI of diff. 
-2.479 to 5.146 
-4.546 to 3.079 
-5.212 to 2.412 







1.208 P > 0.05 ns 
0.6645 P > 0.05 ns 
1.269 P > 0.05 ns 
glucan 10-10 vs. glucanlO-11 
Treatment glucan 10-10 glucanlO-11 Difference 95% CI of diff. 
0.5 1.933 1.533 -0.4 -4.212 to 3.412 
1 6.467 5.5 -0.9667 -4.779 to 2.846 
2 2.667 -2.6 -5.267 -9.079 to -1.454 
Treatment 









































P > 0.05 







P > 0.05 
P > 0.05 





95% CI of diff. 
-3.112 to 4.512 
-5.112 to 2.512 





glucanlO-11 vs. glucan 10-12 
Treatment glucanlO-11 glucan 10-12 Difference 95% CI of diff. 
0.5 1.533 2.633 1.1 -2.712 to 4.912 
1 5.5 5.167 -0.3333 -4.146 to 3.479 













P > 0.05 
P > 0.05 
P<0.01 
Summary 
ns 
ns 
** 
